You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameImipramine
Accession NumberDB00458  (APRD00672, DB08002)
TypeSmall Molecule
GroupsApproved
DescriptionImipramine, the prototypical tricyclic antidepressant (TCA), is a dibenzazepine-derivative TCA. TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, imipramine does not affect mood or arousal, but may cause sedation. In depressed individuals, imipramine exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. Tertiary amine TCAs, such as imipramine and amitriptyline, are more potent inhibitors of serotonin reuptake than secondary amine TCAs, such as nortriptyline and desipramine. TCAs also down-regulate cerebral cortical β-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use. The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. TCAs also block histamine H1 receptors, α1-adrenergic receptors and muscarinic receptors, which accounts for their sedative, hypotensive and anticholinergic effects (e.g. blurred vision, dry mouth, constipation, urinary retention), respectively. Imipramine has less sedative and anticholinergic effects than the tertiary amine TCAs, amitriptyline and clomipramine. See toxicity section below for a complete listing of side effects. Imipramine may be used to treat depression and nocturnal enuresis in children. Unlabeled indications include chronic and neuropathic pain (including diabetic neuropathy), panic disorder, attention-deficit/hyperactivity disorder (ADHD), and post-traumatic stress disorder (PTSD).
Structure
Thumb
Synonyms
10,11-dihydro-N,N-Dimethyl-5H-dibenz[b,F]azepine-5-propanamine
3-(5H-DIBENZO[b,F]azepin-5-yl)-N,N-dimethylpropan-1-amine
5-[3-(dimethylamino)Propyl]-10,11-dihydro-5H-dibenz[b,F]azepine
Antideprin
Imipramin
Imipramine
Imipraminum
Imizine
Irmin
Melipramine
N-(gamma-Dimethylaminopropyl)iminodibenzyl
N-(γ-dimethylaminopropyl)iminodibenzyl
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Imipraminetablet10 mgoralAa Pharma Inc1976-12-31Not applicableCanada
Imipraminetablet75 mgoralAa Pharma Inc1989-12-31Not applicableCanada
Imipraminetablet25 mgoralAa Pharma Inc1975-12-31Not applicableCanada
Imipraminetablet50 mgoralAa Pharma Inc1975-12-31Not applicableCanada
Imipramine 10tabtablet10 mgoralPro Doc Limitee1976-12-312010-07-13Canada
Imipramine 25tabtablet25 mgoralPro Doc Limitee1976-12-312010-07-13Canada
Imipramine 50 Tab 50mgtablet50 mgoralPro Doc Limitee1978-12-312010-07-13Canada
Imipramine Hydrochloride Tablets 25mgtablet25 mgoralD.C. Labs Limited1977-12-312003-07-11Canada
Imipramine Hydrochloride Tablets 50mgtablet50 mgoralD.C. Labs Limited1977-12-312003-07-11Canada
Imipramine Pamoatecapsule150 mg/1oralMallinckrodt, Inc.2009-10-15Not applicableUs
Imipramine Pamoatecapsule75 mg/1oralMallinckrodt, Inc.2009-10-15Not applicableUs
Imipramine Pamoatecapsule75 mg/1oralSTAT Rx USA LLC2009-10-15Not applicableUs
Imipramine Pamoatecapsule100 mg/1oralMallinckrodt, Inc.2009-10-15Not applicableUs
Imipramine Pamoatecapsule125 mg/1oralMallinckrodt, Inc.2009-10-15Not applicableUs
Imipramine Tab 25mgtablet25 mgoralDuchesnay Inc1978-12-312003-07-18Canada
Impriltablet50 mgoralValeant Canada Lp Valeant Canada S.E.C.1974-12-312014-07-30Canada
Impriltablet10 mgoralValeant Canada Lp Valeant Canada S.E.C.1974-12-312014-07-30Canada
Impriltablet75 mgoralValeant Canada Lp Valeant Canada S.E.C.1988-12-312014-07-30Canada
Impriltablet25 mgoralValeant Canada Lp Valeant Canada S.E.C.1974-12-312014-07-30Canada
Novo-pramine Tab 10mgtablet10 mgoralNovopharm Limited1971-12-31Not applicableCanada
Novo-pramine Tab 25mgtablet25 mgoralNovopharm Limited1971-12-31Not applicableCanada
Novo-pramine Tab 50mgtablet50 mgoralNovopharm Limited1971-12-31Not applicableCanada
PMS Imipramine Tab 10mgtablet10 mgoralPharmascience Inc1988-12-31Not applicableCanada
PMS Imipramine Tab 25mgtablet25 mgoralPharmascience Inc1988-12-31Not applicableCanada
PMS Imipramine Tab 50mgtablet50 mgoralPharmascience Inc1988-12-31Not applicableCanada
Tofranil 10mgtablet10 mgoralNovartis Pharmaceuticals Canada Inc1960-12-312001-07-30Canada
Tofranil 25mgtablet25 mgoralNovartis Pharmaceuticals Canada Inc1959-12-312008-07-18Canada
Tofranil 50mgtablet50 mgoralNovartis Pharmaceuticals Canada Inc1962-12-312010-11-29Canada
Tofranil 75mgtablet75 mgoralNovartis Pharmaceuticals Canada Inc1974-12-312008-07-18Canada
Tofranil-PMcapsule75 mg/1oralMallinckrodt, Inc.2009-11-04Not applicableUs
Tofranil-PMcapsule100 mg/1oralMallinckrodt, Inc.2009-11-04Not applicableUs
Tofranil-PMcapsule125 mg/1oralMallinckrodt, Inc.2009-11-04Not applicableUs
Tofranil-PMcapsule150 mg/1oralMallinckrodt, Inc.2009-11-04Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-imipraminetablet25 mgoralApotex IncNot applicableNot applicableCanada
Apo-imipraminetablet50 mgoralApotex IncNot applicableNot applicableCanada
Apo-imipraminetablet75 mgoralApotex IncNot applicableNot applicableCanada
Apo-imipraminetablet10 mgoralApotex IncNot applicableNot applicableCanada
Imipramine Hydrochloridetablet50 mg/1oralGolden State Medical Supply, Inc.1999-08-27Not applicableUs
Imipramine Hydrochloridetablet, film coated10 mg/1oralLupin Pharmaceuticals, Inc.2010-12-21Not applicableUs
Imipramine Hydrochloridetablet, film coated25 mg/1oralA S Medication Solutions Llc1990-06-05Not applicableUs
Imipramine Hydrochloridetablet, film coated25 mg/1oralRichmond Pharmaceuticals, Inc.1990-06-05Not applicableUs
Imipramine Hydrochloridetablet, film coated25 mg/1oralREMEDYREPACK INC.2011-04-21Not applicableUs
Imipramine Hydrochloridetablet, film coated25 mg/1oralExcellium Pharmaceutical, Inc2012-11-01Not applicableUs
Imipramine Hydrochloridetablet, film coated25 mg/1oralLeading Pharma, Llc2016-04-07Not applicableUs
Imipramine Hydrochloridetablet50 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC1983-10-21Not applicableUs
Imipramine Hydrochloridetablet, film coated25 mg/1oralMutual Pharmaceutical Company, Inc.1990-06-05Not applicableUs
Imipramine Hydrochloridetablet, film coated25 mg/1oralPd Rx Pharmaceuticals, Inc.1976-04-20Not applicableUs
Imipramine Hydrochloridetablet10 mg/1oralKAISER FOUNDATION HOSPITALS2012-05-31Not applicableUs
Imipramine Hydrochloridetablet25 mg/1oralPar Pharmaceutical Inc.1983-10-21Not applicableUs
Imipramine Hydrochloridetablet, film coated50 mg/1oralbryant ranch prepack1990-06-05Not applicableUs
Imipramine Hydrochloridetablet, film coated25 mg/1oralLupin Pharmaceuticals, Inc.2010-12-21Not applicableUs
Imipramine Hydrochloridetablet, film coated10 mg/1oralSandoz Inc1976-04-20Not applicableUs
Imipramine Hydrochloridetablet, film coated50 mg/1oralNorthwind Pharmaceuticals, LLC2015-03-06Not applicableUs
Imipramine Hydrochloridetablet, film coated50 mg/1oralRichmond Pharmaceuticals, Inc.1990-06-05Not applicableUs
Imipramine Hydrochloridetablet50 mg/1oralREMEDYREPACK INC.2011-09-20Not applicableUs
Imipramine Hydrochloridetablet, film coated50 mg/1oralMutual Pharmaceutical Company, Inc.1990-06-05Not applicableUs
Imipramine Hydrochloridetablet, film coated50 mg/1oralExcellium Pharmaceutical, Inc2012-11-01Not applicableUs
Imipramine Hydrochloridetablet, film coated50 mg/1oralLeading Pharma, Llc2016-04-07Not applicableUs
Imipramine Hydrochloridetablet, film coated10 mg/1oralAv Kare, Inc.2015-12-09Not applicableUs
Imipramine Hydrochloridetablet50 mg/1oralPar Pharmaceutical Inc.1983-10-21Not applicableUs
Imipramine Hydrochloridetablet10 mg/1oralGolden State Medical Supply, Inc.1999-08-27Not applicableUs
Imipramine Hydrochloridetablet, film coated25 mg/1oralbryant ranch prepack2010-12-21Not applicableUs
Imipramine Hydrochloridetablet, film coated50 mg/1oralLupin Pharmaceuticals, Inc.2010-12-21Not applicableUs
Imipramine Hydrochloridetablet, film coated25 mg/1oralSandoz Inc1976-04-20Not applicableUs
Imipramine Hydrochloridetablet, film coated50 mg/1oralREMEDYREPACK INC.2013-07-08Not applicableUs
Imipramine Hydrochloridetablet, film coated25 mg/1oralPhysicians Total Care, Inc.1993-02-02Not applicableUs
Imipramine Hydrochloridetablet25 mg/1oralREMEDYREPACK INC.2011-09-21Not applicableUs
Imipramine Hydrochloridetablet, film coated25 mg/1oralAv Kare, Inc.2015-12-09Not applicableUs
Imipramine Hydrochloridetablet, film coated25 mg/1oralA S Medication Solutions Llc1990-06-05Not applicableUs
Imipramine Hydrochloridetablet10 mg/1oralCarilion Materials Management1983-10-21Not applicableUs
Imipramine Hydrochloridetablet25 mg/1oralA S Medication Solutions Llc1983-10-21Not applicableUs
Imipramine Hydrochloridetablet25 mg/1oralGolden State Medical Supply, Inc.1999-08-27Not applicableUs
Imipramine Hydrochloridetablet, film coated10 mg/1oralExcellium Pharmaceutical, Inc2012-11-01Not applicableUs
Imipramine Hydrochloridetablet, film coated10 mg/1oralLeading Pharma, Llc2016-04-07Not applicableUs
Imipramine Hydrochloridetablet, film coated50 mg/1oralSandoz Inc1976-04-20Not applicableUs
Imipramine Hydrochloridetablet, film coated10 mg/1oralMutual Pharmaceutical Company, Inc.1990-06-05Not applicableUs
Imipramine Hydrochloridetablet, film coated50 mg/1oralPhysicians Total Care, Inc.1992-11-12Not applicableUs
Imipramine Hydrochloridetablet10 mg/1oralPar Pharmaceutical Inc.1983-10-21Not applicableUs
Imipramine Hydrochloridetablet, film coated50 mg/1oralAv Kare, Inc.2015-12-09Not applicableUs
Imipramine Hydrochloridetablet, film coated10 mg/1oralRichmond Pharmaceuticals, Inc.1990-06-05Not applicableUs
Imipramine Pamoatecapsule100 mg/1oralLupin Pharmaceuticals, Inc.2010-04-16Not applicableUs
Imipramine Pamoatecapsule75 mg/1oralRoxane Laboratories, Inc2010-04-19Not applicableUs
Imipramine Pamoatecapsule125 mg/1oralLupin Pharmaceuticals, Inc.2010-04-16Not applicableUs
Imipramine Pamoatecapsule100 mg/1oralRoxane Laboratories, Inc2010-04-19Not applicableUs
Imipramine Pamoatecapsule150 mg/1oralLupin Pharmaceuticals, Inc.2010-04-16Not applicableUs
Imipramine Pamoatecapsule125 mg/1oralRoxane Laboratories, Inc2010-04-19Not applicableUs
Imipramine Pamoatecapsule150 mg/1oralRoxane Laboratories, Inc2010-04-19Not applicableUs
Imipramine Pamoatecapsule75 mg/1oralLupin Pharmaceuticals, Inc.2010-04-16Not applicableUs
Tofraniltablet, sugar coated50 mg/1oralMallinckrodt, Inc.2011-01-24Not applicableUs
Tofraniltablet, sugar coated10 mg/1oralMallinckrodt, Inc.2011-01-24Not applicableUs
Tofraniltablet, sugar coated25 mg/1oralMallinckrodt, Inc.2011-01-24Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AntidepTorrent
DepsonilAbbott
Depsonil-PMAbbott
ElaminBaroda
FronilJohnson
ImidolTanabe Mitsubishi Pharma
Imipramin DakNycomed
ImiprexDumex
PraminIncepta
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Imipramine Hydrochloride
113-52-0
Thumb
  • InChI Key: XZZXIYZZBJDEEP-UHFFFAOYSA-N
  • Monoisotopic Mass: 316.170626517
  • Average Mass: 316.868
DBSALT000099
Imipramine Pamoate
Thumb
  • InChI Key: SBDXQUVAAJKLDH-UHFFFAOYSA-N
  • Monoisotopic Mass: 668.288637022
  • Average Mass: 668.7768
DBSALT000100
Categories
UNIIOGG85SX4E4
CAS number50-49-7
WeightAverage: 280.4073
Monoisotopic: 280.193948778
Chemical FormulaC19H24N2
InChI KeyInChIKey=BCGWQEUPMDMJNV-UHFFFAOYSA-N
InChI
InChI=1S/C19H24N2/c1-20(2)14-7-15-21-18-10-5-3-8-16(18)12-13-17-9-4-6-11-19(17)21/h3-6,8-11H,7,12-15H2,1-2H3
IUPAC Name
(3-{2-azatricyclo[9.4.0.0³,⁸]pentadeca-1(15),3,5,7,11,13-hexaen-2-yl}propyl)dimethylamine
SMILES
CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as dibenzazepines. These are compounds with two benzene rings connected by an azepine ring. Azepine is an unsaturated seven-member heterocycle with one nitrogen atom replacing a carbon atom.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzazepines
Sub ClassDibenzazepines
Direct ParentDibenzazepines
Alternative Parents
Substituents
  • Dibenzazepine
  • Alkyldiarylamine
  • Azepine
  • Benzenoid
  • Tertiary aliphatic amine
  • Tertiary amine
  • Azacycle
  • Hydrocarbon derivative
  • Organonitrogen compound
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFor the relief of symptoms of depression and as temporary adjunctive therapy in reducing enuresis in children aged 6 years and older. May also be used to manage panic disorders, with or without agoraphobia, as a second line agent in ADHD, management of eating disorders, for short-term management of acute depressive episodes in bipolar disorder and schizophrenia, and for symptomatic treatment of postherpetic neuralgia.
PharmacodynamicsImipramine is a tricyclic antidepressant with general pharmacological properties similar to those of structurally related tricyclic antidepressant drugs such as amitriptyline and doxepin. A tertiary amine, imipramine inhibits the reuptake of serotonin more so than most secondary amine tricyclics, meaning that it blocks the reuptake of neurotransmitters serotonin and noradrenaline almost equally. With chronic use, imipramine also down-regulates cerebral cortical β-adrenergic receptors and sensitizes post-synaptic sertonergic receptors, which also contributes to increased serotonergic transmission. It takes approximately 2 - 4 weeks for antidepressants effects to occur. The onset of action may be longer, up to 8 weeks, in some individuals. It is also effective in migraine prophylaxis, but not in abortion of acute migraine attack.
Mechanism of actionImipramine works by inhibiting the neuronal reuptake of the neurotransmitters norepinephrine and serotonin. It binds the sodium-dependent serotonin transporter and sodium-dependent norepinephrine transporter preventing or reducing the reuptake of norepinephrine and serotonin by nerve cells. Depression has been linked to a lack of stimulation of the post-synaptic neuron by norepinephrine and serotonin. Slowing the reuptake of these neurotransmitters increases their concentration in the synaptic cleft, which is thought to contribute to relieving symptoms of depression. In addition to acutely inhibiting neurotransmitter re-uptake, imipramine causes down-regulation of cerebral cortical beta-adrenergic receptors and sensitization of post-synaptic serotonergic receptors with chronic use. This leads to enhanced serotonergic transmission.
Related Articles
AbsorptionRapidly and well absorbed after oral administration. Bioavailability is approximately 43%. Peak plasma concentrations usually attained 1 - 2 hours following oral administration. Absorption is unaffected by food.
Volume of distributionNot Available
Protein binding60-95%
Metabolism

Exclusively metabolized by the liver. Imipramine is converted in the liver by various CYP isoenzymes (e.g. CYP1A2, CYP2D6, CYP3A4, CYP2C9) to active metabolites desipramine and 2-hydroxydesipramine.

SubstrateEnzymesProduct
Imipramine
2-hydroxyimipramineDetails
Imipramine
DesipramineDetails
2-hydroxyimipramine
Not Available
2-hydroxy-imipramine glucuronideDetails
Route of eliminationApproximately 40% of an orally administered dose is eliminated in urine within 24 hours, 70% in 72 hours. Small amounts are eliminated in feces via the biliary elimination.
Half lifeImipramine - 8-20 hours; Desipramine (active metabolite) - up to 125 hours
ClearanceNot Available
ToxicityOral, rat LD50: 355 to 682 mg/kg. Toxic signs proceed progressively from depression, irregular respiration and ataxia to convulsions and death. Antagonism of the histamine H1 and α1 receptors can lead to sedation and hypotension. Antimuscarinic and anticholinergic side effects such as blurred vision, dry mouth, constipation and urine retention may occur. Cardiotoxicity may occur with high doses of imipramine. Cardiovascular side effects in postural hypotension, tachycardia, hypertension, ECG changes and congestive heart failure. Psychotoxic effects include impaired memory and delirium. Induction of hypomanic or manic episodes may occur in patients with a history of bipolar disorder. Withdrawal symptoms include GI disturbances (e.g. nausea, vomiting, abdominal pain, diarrhea), anxiety, insomnia, nervousness, headache and malaise.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Imipramine Metabolism PathwayDrug metabolismSMP00625
Imipramine Action PathwayDrug actionSMP00422
SNP Mediated Effects
Interacting Gene/EnzymeSNP RS IDAllele nameDefining changeEffectReference(s)
Cytochrome P450 2D6
Gene symbol: CYP2D6
UniProt: P10635
rs3892097 CYP2D6*4A AllelePoor drug metabolizer, lower dose requirements, higher risk for adverse side effects18070221
SNP Mediated Adverse Drug Reactions
Interacting Gene/EnzymeSNP RS IDAllele nameDefining changeAdverse ReactionReference(s)
Cytochrome P450 2D6
Gene symbol: CYP2D6
UniProt: P10635
rs3892097 CYP2D6*4C > TThose that are homozygous for the poorly metabolizing CYP2D6 alleles are at an increased risk of side effects and decrease drug metabolism18070221
Cytochrome P450 2D6
Gene symbol: CYP2D6
UniProt: P10635
rs3892097 CYP2D6*4C > TThose that are homozygous for the poorly metabolizing CYP2D6 alleles are at an increased risk of side effects and decrease drug metabolism9918137
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9822
Blood Brain Barrier+0.9865
Caco-2 permeable+0.8867
P-glycoprotein substrateSubstrate0.7684
P-glycoprotein inhibitor IInhibitor0.8662
P-glycoprotein inhibitor IIInhibitor0.6205
Renal organic cation transporterInhibitor0.8541
CYP450 2C9 substrateNon-substrate0.7799
CYP450 2D6 substrateSubstrate0.9532
CYP450 3A4 substrateSubstrate0.6718
CYP450 1A2 substrateNon-inhibitor0.7583
CYP450 2C9 inhibitorNon-inhibitor0.9089
CYP450 2D6 inhibitorInhibitor0.9017
CYP450 2C19 inhibitorNon-inhibitor0.9304
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8399
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.9329
BiodegradationNot ready biodegradable0.9819
Rat acute toxicity3.0187 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9172
hERG inhibition (predictor II)Inhibitor0.7771
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Novartis pharmaceuticals corp
  • Actavis totowa llc
  • Lederle laboratories div american cyanamid co
  • Lupin ltd
  • Mutual pharmaceutical co inc
  • Par pharmaceutical inc
  • Roxane laboratories inc
  • Sandoz inc
  • Teva pharmaceuticals usa inc
  • Usl pharma inc
  • Vangard laboratories inc div midway medical co
  • Watson laboratories inc
  • West ward pharmaceutical corp
  • Abbott laboratories pharmaceutical products div
  • Alra laboratories inc
  • Sanofi aventis us llc
  • Tyco healthcare group lp
  • Odyssey pharmaceuticals inc
Packagers
Dosage forms
FormRouteStrength
Tabletoral75 mg
Tabletoral10 mg/1
Tabletoral25 mg/1
Tabletoral50 mg/1
Tablet, film coatedoral10 mg/1
Tablet, film coatedoral25 mg/1
Tablet, film coatedoral50 mg/1
Capsuleoral100 mg/1
Capsuleoral125 mg/1
Capsuleoral150 mg/1
Capsuleoral75 mg/1
Tabletoral10 mg
Tabletoral25 mg
Tabletoral50 mg
Tablet, sugar coatedoral10 mg/1
Tablet, sugar coatedoral25 mg/1
Tablet, sugar coatedoral50 mg/1
Prices
Unit descriptionCostUnit
Tofranil-PM 30 125 mg capsule Bottle588.33USD bottle
Tofranil-PM 30 150 mg capsule Bottle588.33USD bottle
Tofranil-PM 30 75 mg capsule Bottle588.33USD bottle
Tofranil 30 50 mg tablet Bottle185.09USD bottle
Trimipramine maleate powder51.0USD g
Tofranil-pm 100 mg capsule19.23USD capsule
Tofranil-pm 150 mg capsule18.86USD capsule
Tofranil-pm 75 mg capsule18.86USD capsule
Tofranil-pm 125 mg capsule18.68USD capsule
Imipramine pamoate 75 mg capsule16.35USD capsule
Imipramine pamoate 100 mg capsule15.17USD capsule
Imipramine pamoate 125 mg capsule15.17USD capsule
Imipramine pamoate 150 mg capsule15.17USD capsule
Tofranil 50 mg tablet6.64USD tablet
Surmontil 100 mg capsule5.92USD capsule
Tofranil 25 mg tablet4.97USD tablet
Tofranil 10 mg tablet4.73USD tablet
Surmontil 50 mg capsule4.07USD capsule
Trimipramine Maleate 50 mg capsule3.27USD capsule
Trimipramine 50 mg capsule3.14USD capsule
Surmontil 25 mg capsule2.49USD capsule
Cenestin 0.3 mg tablet2.21USD tablet
Cenestin 0.45 mg tablet2.21USD tablet
Cenestin 0.625 mg tablet2.21USD tablet
Cenestin 0.9 mg tablet2.21USD tablet
Cenestin 1.25 mg tablet2.21USD tablet
Trimipramine 25 mg capsule1.92USD capsule
Apo-Trimip 100 mg Tablet0.97USD tablet
Imipramine hcl powder0.77USD g
Apo-Trimip 75 mg Capsule0.77USD capsule
Apo-Imipramine 75 mg Tablet0.58USD tablet
Tofranil 50 mg Tablet0.57USD tablet
Apo-Trimip 50 mg Tablet0.57USD tablet
Imipramine hcl 10 mg tablet0.46USD tablet
Imipramine hcl 50 mg tablet0.44USD tablet
Apo-Imipramine 50 mg Tablet0.4USD tablet
Imipramine hcl 25 mg tablet0.35USD tablet
Apo-Trimip 25 mg Tablet0.29USD tablet
Apo-Imipramine 25 mg Tablet0.25USD tablet
Apo-Trimip 12.5 mg Tablet0.23USD tablet
Apo-Imipramine 10 mg Tablet0.14USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point174-175U.S. Patent 2,554,736.
boiling point160 °C at 1.00E-01 mm HgPhysProp
water solubility18.2 mg/L (at 24 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP4.80HANSCH,C ET AL. (1995)
logS-4.19ADME Research, USCD
Caco2 permeability-4.85ADME Research, USCD
pKa9.4SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility0.0664 mg/mLALOGPS
logP4.53ALOGPS
logP4.28ChemAxon
logS-3.6ALOGPS
pKa (Strongest Basic)9.2ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area6.48 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity90.61 m3·mol-1ChemAxon
Polarizability33.39 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (10.2 KB)
Spectra
Spectrum TypeDescriptionSplash Key
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 10V, Positive (Annotated)splash10-000i-9000000000-55d924fd00e5b357ce9eView in MoNA
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 25V, Positive (Annotated)splash10-000i-9000000000-eb3c0ecdffc5d9d95e33View in MoNA
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 40V, Positive (Annotated)splash10-0ab9-9432000000-033c51459b692622ee7dView in MoNA
LC-MS/MSLC-MS/MS Spectrum - EI-B (Unknown) , Positivesplash10-0019-7490000000-bb99ef31a755d9f6ba14View in MoNA
MSMass Spectrum (Electron Ionization)splash10-0543-8890000000-6cf8e84f007ce7c750f2View in MoNA
1D NMR1H NMR SpectrumNot Available
2D NMR[1H,13C] 2D NMR SpectrumNot Available
References
Synthesis Reference

U.S. Patent 2,554,736.

General ReferencesNot Available
External Links
ATC CodesN06AA02
AHFS Codes
  • 28:16.04.28
PDB EntriesNot Available
FDA labelDownload (152 KB)
MSDSDownload (73.6 KB)
Interactions
Drug Interactions
Drug
1,10-PhenanthrolineThe serum concentration of Imipramine can be increased when it is combined with 1,10-Phenanthroline.
3,4-DichloroisocoumarinThe serum concentration of Imipramine can be increased when it is combined with 3,4-Dichloroisocoumarin.
3,4-MethylenedioxyamphetamineImipramine may increase the stimulatory activities of 3,4-Methylenedioxyamphetamine.
3,4-MethylenedioxymethamphetamineImipramine may increase the stimulatory activities of 3,4-Methylenedioxymethamphetamine.
4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDEThe serum concentration of Imipramine can be increased when it is combined with 4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDE.
4-MethoxyamphetamineThe therapeutic efficacy of 4-Methoxyamphetamine can be decreased when used in combination with Imipramine.
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Imipramine.
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the serotonergic activities of Imipramine.
AbirateroneThe serum concentration of Imipramine can be increased when it is combined with Abiraterone.
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Imipramine.
AcenocoumarolImipramine may increase the anticoagulant activities of Acenocoumarol.
AcepromazineThe risk or severity of adverse effects can be increased when Imipramine is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Imipramine is combined with Aceprometazine.
AcetaminophenThe serum concentration of Imipramine can be increased when it is combined with Acetaminophen.
AcetophenazineThe risk or severity of adverse effects can be increased when Imipramine is combined with Acetophenazine.
AcetylcholineThe metabolism of Acetylcholine can be decreased when combined with Imipramine.
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Imipramine.
adipiplonThe risk or severity of adverse effects can be increased when adipiplon is combined with Imipramine.
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Imipramine.
AgmatineThe therapeutic efficacy of Agmatine can be decreased when used in combination with Imipramine.
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Imipramine.
AjmalineThe metabolism of Ajmaline can be decreased when combined with Imipramine.
AlbendazoleThe serum concentration of Imipramine can be increased when it is combined with Albendazole.
AldosteroneThe serum concentration of Imipramine can be decreased when it is combined with Aldosterone.
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Imipramine.
AlectinibThe serum concentration of Imipramine can be increased when it is combined with Alectinib.
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Imipramine.
AlfentanilThe serum concentration of Imipramine can be increased when it is combined with Alfentanil.
AlfentanilThe risk or severity of adverse effects can be increased when Imipramine is combined with Alfentanil.
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Imipramine.
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Imipramine.
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Imipramine.
AlogliptinThe serum concentration of Imipramine can be increased when it is combined with Alogliptin.
AlogliptinThe metabolism of Alogliptin can be decreased when combined with Imipramine.
Alpha-1-proteinase inhibitorThe serum concentration of Imipramine can be increased when it is combined with Alpha-1-proteinase inhibitor.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Imipramine.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Imipramine.
AlprenololThe metabolism of Alprenolol can be decreased when combined with Imipramine.
AltretamineAltretamine may increase the orthostatic hypotensive activities of Imipramine.
AmantadineThe serum concentration of Imipramine can be increased when it is combined with Amantadine.
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Imipramine.
Aminohippuric acidThe serum concentration of Imipramine can be increased when it is combined with Aminohippuric acid.
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Imipramine.
AmiodaroneThe serum concentration of Imipramine can be decreased when it is combined with Amiodarone.
AmiodaroneThe metabolism of Amiodarone can be decreased when combined with Imipramine.
AmisulprideThe risk or severity of adverse effects can be increased when Imipramine is combined with Amisulpride.
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Imipramine.
AmlodipineThe serum concentration of Imipramine can be increased when it is combined with Amlodipine.
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Imipramine.
AmoxapineThe risk or severity of adverse effects can be increased when Imipramine is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Imipramine is combined with Amperozide.
AmphetamineImipramine may increase the stimulatory activities of Amphetamine.
AmprenavirThe serum concentration of Imipramine can be increased when it is combined with Amprenavir.
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Imipramine.
AmsacrineThe serum concentration of Imipramine can be increased when it is combined with Amsacrine.
AmsacrineThe metabolism of Amsacrine can be decreased when combined with Imipramine.
AnagrelideImipramine may increase the QTc-prolonging activities of Anagrelide.
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Imipramine.
Antithrombin III humanThe serum concentration of Imipramine can be increased when it is combined with Antithrombin III human.
ApixabanThe serum concentration of Imipramine can be increased when it is combined with Apixaban.
ApomorphineThe therapeutic efficacy of Apomorphine can be decreased when used in combination with Imipramine.
ApraclonidineThe therapeutic efficacy of Apraclonidine can be decreased when used in combination with Imipramine.
AprepitantThe serum concentration of Imipramine can be increased when it is combined with Aprepitant.
AprindineThe metabolism of Aprindine can be decreased when combined with Imipramine.
AprotininThe serum concentration of Imipramine can be increased when it is combined with Aprotinin.
ArbutamineThe risk or severity of adverse effects can be increased when Imipramine is combined with Arbutamine.
ArformoterolThe risk or severity of adverse effects can be increased when Imipramine is combined with Arformoterol.
ArgatrobanThe serum concentration of Imipramine can be increased when it is combined with Argatroban.
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Imipramine.
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Imipramine.
ArmodafinilThe metabolism of Imipramine can be decreased when combined with Armodafinil.
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Imipramine.
ArtemetherThe metabolism of Artemether can be decreased when combined with Imipramine.
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Imipramine.
AsenapineThe risk or severity of adverse effects can be increased when Imipramine is combined with Asenapine.
AstemizoleThe serum concentration of Imipramine can be increased when it is combined with Astemizole.
AstemizoleThe metabolism of Astemizole can be decreased when combined with Imipramine.
AsunaprevirThe serum concentration of Imipramine can be increased when it is combined with Asunaprevir.
AtazanavirThe serum concentration of Imipramine can be increased when it is combined with Atazanavir.
AtenololThe serum concentration of Imipramine can be increased when it is combined with Atenolol.
AtomoxetineThe metabolism of Imipramine can be decreased when combined with Atomoxetine.
AtorvastatinThe serum concentration of Imipramine can be increased when it is combined with Atorvastatin.
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Imipramine.
AzaperoneThe risk or severity of adverse effects can be increased when Imipramine is combined with Azaperone.
AzelastineImipramine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe serum concentration of Imipramine can be increased when it is combined with Azelastine.
AzithromycinImipramine may increase the QTc-prolonging activities of Azithromycin.
AzithromycinThe serum concentration of Imipramine can be increased when it is combined with Azithromycin.
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Imipramine.
BambuterolThe risk or severity of adverse effects can be increased when Imipramine is combined with Bambuterol.
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Imipramine.
BatimastatThe serum concentration of Imipramine can be increased when it is combined with Batimastat.
BedaquilineImipramine may increase the QTc-prolonging activities of Bedaquiline.
BenazeprilThe serum concentration of Imipramine can be increased when it is combined with Benazepril.
BenmoxinBenmoxin may increase the serotonergic activities of Imipramine.
BenzamidineThe serum concentration of Imipramine can be increased when it is combined with Benzamidine.
BenzatropineThe metabolism of Benzatropine can be decreased when combined with Imipramine.
BenzocaineThe serum concentration of Imipramine can be increased when it is combined with Benzocaine.
BenzocaineThe risk or severity of adverse effects can be increased when Imipramine is combined with Benzocaine.
BenzphetamineImipramine may increase the stimulatory activities of Benzphetamine.
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Imipramine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Imipramine.
BepridilThe serum concentration of Imipramine can be increased when it is combined with Bepridil.
BepridilThe metabolism of Bepridil can be decreased when combined with Imipramine.
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Imipramine.
BetaxololThe metabolism of Imipramine can be decreased when combined with Betaxolol.
BethanidineThe therapeutic efficacy of Bethanidine can be decreased when used in combination with Imipramine.
BexaroteneThe serum concentration of Imipramine can be decreased when it is combined with Bexarotene.
BifeprunoxThe risk or severity of adverse effects can be increased when Imipramine is combined with Bifeprunox.
BiperidenThe serum concentration of Imipramine can be increased when it is combined with Biperiden.
BisoprololThe metabolism of Bisoprolol can be decreased when combined with Imipramine.
BivalirudinThe serum concentration of Imipramine can be increased when it is combined with Bivalirudin.
BoceprevirThe serum concentration of Imipramine can be increased when it is combined with Boceprevir.
BortezomibThe metabolism of Imipramine can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Imipramine can be decreased when it is combined with Bosentan.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Imipramine.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Imipramine.
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Imipramine.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Brexpiprazole is combined with Imipramine.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Imipramine.
BrimonidineThe therapeutic efficacy of Brimonidine can be decreased when used in combination with Imipramine.
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Imipramine.
BromocriptineThe therapeutic efficacy of Bromocriptine can be decreased when used in combination with Imipramine.
BromocriptineThe serum concentration of Imipramine can be increased when it is combined with Bromocriptine.
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Imipramine.
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Imipramine.
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Imipramine.
BufuralolThe metabolism of Bufuralol can be decreased when combined with Imipramine.
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Imipramine.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Imipramine.
BuprenorphineThe serum concentration of Imipramine can be increased when it is combined with Buprenorphine.
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Imipramine.
BupropionThe metabolism of Imipramine can be decreased when combined with Bupropion.
BuspironeThe serum concentration of Imipramine can be increased when it is combined with Buspirone.
BuspironeThe metabolism of Buspirone can be decreased when combined with Imipramine.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Imipramine.
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Imipramine.
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Imipramine.
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Imipramine.
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Imipramine.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Imipramine.
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Imipramine.
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Imipramine.
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Imipramine.
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Imipramine.
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Imipramine.
CandesartanThe serum concentration of Imipramine can be increased when it is combined with Candesartan.
CandoxatrilThe serum concentration of Imipramine can be increased when it is combined with Candoxatril.
CaptoprilThe serum concentration of Imipramine can be increased when it is combined with Captopril.
CaptoprilThe metabolism of Captopril can be decreased when combined with Imipramine.
CarbamazepineThe metabolism of Imipramine can be increased when combined with Carbamazepine.
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Imipramine.
CarbinoxamineThe risk or severity of adverse effects can be increased when Imipramine is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Imipramine.
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Imipramine.
CariprazineThe risk or severity of adverse effects can be increased when Imipramine is combined with Cariprazine.
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Imipramine.
CaroxazoneCaroxazone may increase the serotonergic activities of Imipramine.
CarteololThe metabolism of Carteolol can be decreased when combined with Imipramine.
CarvedilolThe serum concentration of Imipramine can be increased when it is combined with Carvedilol.
CarvedilolThe metabolism of Carvedilol can be decreased when combined with Imipramine.
CaspofunginThe serum concentration of Imipramine can be increased when it is combined with Caspofungin.
CelecoxibThe metabolism of Imipramine can be decreased when combined with Celecoxib.
CeliprololThe risk or severity of adverse effects can be increased when Imipramine is combined with Celiprolol.
CephalexinThe metabolism of Cephalexin can be decreased when combined with Imipramine.
CeritinibThe serum concentration of Imipramine can be increased when it is combined with Ceritinib.
CeritinibImipramine may increase the QTc-prolonging activities of Ceritinib.
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Imipramine.
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Imipramine.
CevimelineThe metabolism of Cevimeline can be decreased when combined with Imipramine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Imipramine.
ChloramphenicolThe metabolism of Imipramine can be decreased when combined with Chloramphenicol.
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Imipramine.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Imipramine.
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Imipramine.
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Imipramine.
ChloroquineImipramine may increase the QTc-prolonging activities of Chloroquine.
ChloroquineThe serum concentration of Imipramine can be increased when it is combined with Chloroquine.
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Imipramine.
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Imipramine.
ChlorphentermineImipramine may increase the stimulatory activities of Chlorphentermine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Imipramine is combined with Chlorpromazine.
ChlorpromazineThe serum concentration of Imipramine can be increased when it is combined with Chlorpromazine.
ChlorpropamideThe serum concentration of Imipramine can be increased when it is combined with Chlorpropamide.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Imipramine is combined with Chlorprothixene.
ChlorprothixeneThe serum concentration of Imipramine can be increased when it is combined with Chlorprothixene.
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Imipramine.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Imipramine.
CholecalciferolThe metabolism of Imipramine can be decreased when combined with Cholecalciferol.
CholesterolThe serum concentration of Imipramine can be increased when it is combined with Cholesterol.
Cholic AcidThe serum concentration of Imipramine can be decreased when it is combined with Cholic Acid.
ChymostatinThe serum concentration of Imipramine can be increased when it is combined with Chymostatin.
CilastatinThe serum concentration of Imipramine can be increased when it is combined with Cilastatin.
CilazaprilThe serum concentration of Imipramine can be increased when it is combined with Cilazapril.
CilostazolThe metabolism of Cilostazol can be decreased when combined with Imipramine.
CimetidineThe metabolism of Imipramine can be decreased when combined with Cimetidine.
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Imipramine.
CinacalcetThe serum concentration of Imipramine can be increased when it is combined with Cinacalcet.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Imipramine.
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Imipramine.
CiprofloxacinImipramine may increase the QTc-prolonging activities of Ciprofloxacin.
CiprofloxacinThe serum concentration of Imipramine can be increased when it is combined with Ciprofloxacin.
CirazolineImipramine may increase the vasopressor activities of Cirazoline.
CisaprideImipramine may increase the QTc-prolonging activities of Cisapride.
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Imipramine.
CitalopramThe risk or severity of adverse effects can be increased when Imipramine is combined with Citalopram.
CitalopramThe serum concentration of Imipramine can be increased when it is combined with Citalopram.
ClarithromycinImipramine may increase the QTc-prolonging activities of Clarithromycin.
ClarithromycinThe serum concentration of Imipramine can be increased when it is combined with Clarithromycin.
ClemastineThe metabolism of Imipramine can be decreased when combined with Clemastine.
ClemastineThe risk or severity of adverse effects can be increased when Imipramine is combined with Clemastine.
ClenbuterolThe risk or severity of adverse effects can be increased when Imipramine is combined with Clenbuterol.
ClevidipineThe metabolism of Clevidipine can be decreased when combined with Imipramine.
ClidiniumThe risk or severity of adverse effects can be increased when Imipramine is combined with Clidinium.
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Imipramine.
ClobazamThe metabolism of Imipramine can be decreased when combined with Clobazam.
ClofazimineThe serum concentration of Imipramine can be increased when it is combined with Clofazimine.
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Imipramine.
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Imipramine.
ClomipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Clomipramine.
ClomipramineThe serum concentration of Imipramine can be increased when it is combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Imipramine is combined with Clonazepam.
ClonidineThe therapeutic efficacy of Clonidine can be decreased when used in combination with Imipramine.
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Imipramine.
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Imipramine.
ClopidogrelThe metabolism of Imipramine can be decreased when combined with Clopidogrel.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Imipramine.
ClotrimazoleThe metabolism of Imipramine can be decreased when combined with Clotrimazole.
ClozapineThe risk or severity of adverse effects can be increased when Imipramine is combined with Clozapine.
ClozapineThe metabolism of Imipramine can be decreased when combined with Clozapine.
CobicistatThe serum concentration of Imipramine can be increased when it is combined with Cobicistat.
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Imipramine.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Imipramine.
CodeineThe therapeutic efficacy of Codeine can be decreased when used in combination with Imipramine.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Imipramine.
ColchicineThe serum concentration of Imipramine can be increased when it is combined with Colchicine.
ColforsinThe serum concentration of Imipramine can be increased when it is combined with Colforsin.
ConivaptanThe serum concentration of Imipramine can be increased when it is combined with Conivaptan.
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Imipramine.
CrizotinibImipramine may increase the QTc-prolonging activities of Crizotinib.
CrizotinibThe metabolism of Imipramine can be decreased when combined with Crizotinib.
CyamemazineThe risk or severity of adverse effects can be increased when Imipramine is combined with Cyamemazine.
CyclizineThe risk or severity of adverse effects can be increased when Imipramine is combined with Cyclizine.
CyclobenzaprineThe metabolism of Cyclobenzaprine can be decreased when combined with Imipramine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Imipramine.
CyclophosphamideThe serum concentration of Imipramine can be increased when it is combined with Cyclophosphamide.
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Imipramine.
CyclosporineThe metabolism of Imipramine can be decreased when combined with Cyclosporine.
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Imipramine.
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Imipramine.
Cyproterone acetateThe serum concentration of Imipramine can be decreased when it is combined with Cyproterone acetate.
Dabigatran etexilateThe serum concentration of Imipramine can be increased when it is combined with Dabigatran etexilate.
DabrafenibThe serum concentration of Imipramine can be decreased when it is combined with Dabrafenib.
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Imipramine.
DaclatasvirThe serum concentration of Imipramine can be increased when it is combined with Daclatasvir.
DactinomycinThe serum concentration of Imipramine can be increased when it is combined with Dactinomycin.
DantroleneThe risk or severity of adverse effects can be increased when Imipramine is combined with Dantrolene.
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Imipramine.
DapiprazoleThe risk or severity of adverse effects can be increased when Imipramine is combined with Dapiprazole.
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Imipramine.
DarifenacinThe metabolism of Darifenacin can be decreased when combined with Imipramine.
DarunavirThe serum concentration of Imipramine can be increased when it is combined with Darunavir.
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Imipramine.
DasatinibThe serum concentration of Imipramine can be increased when it is combined with Dasatinib.
DaunorubicinThe serum concentration of Imipramine can be decreased when it is combined with Daunorubicin.
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Imipramine.
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Imipramine.
DeferasiroxThe serum concentration of Imipramine can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Imipramine can be decreased when combined with Delavirdine.
deramciclaneThe risk or severity of adverse effects can be increased when deramciclane is combined with Imipramine.
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Imipramine.
DesipramineThe serum concentration of Imipramine can be increased when it is combined with Desipramine.
DesipramineThe metabolism of Desipramine can be decreased when combined with Imipramine.
DesloratadineThe serum concentration of Imipramine can be increased when it is combined with Desloratadine.
DesloratadineThe risk or severity of adverse effects can be increased when Imipramine is combined with Desloratadine.
DesmopressinThe risk or severity of adverse effects can be increased when Imipramine is combined with Desmopressin.
DesvenlafaxineThe risk or severity of adverse effects can be increased when Imipramine is combined with Desvenlafaxine.
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Imipramine.
DexamethasoneThe serum concentration of Imipramine can be decreased when it is combined with Dexamethasone.
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Imipramine.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Imipramine.
DexfenfluramineThe metabolism of Dexfenfluramine can be decreased when combined with Imipramine.
DexmedetomidineThe therapeutic efficacy of Dexmedetomidine can be decreased when used in combination with Imipramine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Imipramine.
DexmethylphenidateThe risk or severity of adverse effects can be increased when Dexmethylphenidate is combined with Imipramine.
DexmethylphenidateThe metabolism of Dexmethylphenidate can be decreased when combined with Imipramine.
DextroamphetamineImipramine may increase the stimulatory activities of Dextroamphetamine.
DextromethorphanThe serum concentration of Imipramine can be increased when it is combined with Dextromethorphan.
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Imipramine.
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Imipramine.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Imipramine.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Imipramine.
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Imipramine.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Imipramine.
DiclofenacThe serum concentration of Imipramine can be increased when it is combined with Diclofenac.
DicoumarolImipramine may increase the anticoagulant activities of Dicoumarol.
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Imipramine.
DifenoxinThe risk or severity of adverse effects can be increased when Imipramine is combined with Difenoxin.
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Imipramine.
DigoxinThe serum concentration of Imipramine can be decreased when it is combined with Digoxin.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Imipramine.
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Imipramine.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Imipramine.
DihydroergotamineThe therapeutic efficacy of Dihydroergotamine can be decreased when used in combination with Imipramine.
DihydroergotamineThe metabolism of Imipramine can be decreased when combined with Dihydroergotamine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Imipramine.
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Imipramine.
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Imipramine.
DiltiazemThe metabolism of Imipramine can be decreased when combined with Diltiazem.
DiltiazemThe serum concentration of Diltiazem can be increased when it is combined with Imipramine.
DimenhydrinateThe risk or severity of adverse effects can be increased when Imipramine is combined with Dimenhydrinate.
DiphenhydramineThe metabolism of Diphenhydramine can be decreased when combined with Imipramine.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Imipramine.
DipivefrinThe therapeutic efficacy of Dipivefrin can be decreased when used in combination with Imipramine.
DipyridamoleThe serum concentration of Imipramine can be increased when it is combined with Dipyridamole.
DisopyramideImipramine may increase the QTc-prolonging activities of Disopyramide.
DobutamineThe risk or severity of adverse effects can be increased when Imipramine is combined with Dobutamine.
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Imipramine.
DofetilideImipramine may increase the QTc-prolonging activities of Dofetilide.
DolasetronImipramine may increase the QTc-prolonging activities of Dolasetron.
DolasetronDolasetron may increase the serotonergic activities of Imipramine.
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Imipramine.
DonepezilThe metabolism of Donepezil can be decreased when combined with Imipramine.
DopamineThe metabolism of Dopamine can be decreased when combined with Imipramine.
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Imipramine.
DoxazosinThe serum concentration of Imipramine can be increased when it is combined with Doxazosin.
DoxazosinThe metabolism of Doxazosin can be decreased when combined with Imipramine.
DoxepinThe serum concentration of Imipramine can be increased when it is combined with Doxepin.
DoxepinThe metabolism of Doxepin can be decreased when combined with Imipramine.
DoxorubicinThe serum concentration of Imipramine can be decreased when it is combined with Doxorubicin.
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Imipramine.
DoxycyclineThe metabolism of Imipramine can be decreased when combined with Doxycycline.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Imipramine.
DoxylamineThe risk or severity of adverse effects can be increased when Imipramine is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Imipramine.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Imipramine.
DronedaroneThe metabolism of Imipramine can be decreased when combined with Dronedarone.
DroperidolThe risk or severity of adverse effects can be increased when Imipramine is combined with Droperidol.
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Imipramine.
DroxidopaThe therapeutic efficacy of Droxidopa can be decreased when used in combination with Imipramine.
DuloxetineThe metabolism of Duloxetine can be decreased when combined with Imipramine.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Imipramine.
EcabetThe serum concentration of Imipramine can be increased when it is combined with Ecabet.
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Imipramine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Imipramine.
EdoxabanThe serum concentration of Imipramine can be increased when it is combined with Edoxaban.
EfavirenzThe serum concentration of Imipramine can be decreased when it is combined with Efavirenz.
EfavirenzThe risk or severity of adverse effects can be increased when Imipramine is combined with Efavirenz.
ElafinThe serum concentration of Imipramine can be increased when it is combined with Elafin.
ElbasvirThe serum concentration of Imipramine can be increased when it is combined with Elbasvir.
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Imipramine.
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Imipramine.
EliglustatThe metabolism of Eliglustat can be decreased when combined with Imipramine.
EnalaprilThe serum concentration of Imipramine can be increased when it is combined with Enalapril.
EnalaprilatThe serum concentration of Imipramine can be increased when it is combined with Enalaprilat.
EnalkirenThe serum concentration of Imipramine can be increased when it is combined with Enalkiren.
EncainideThe metabolism of Encainide can be decreased when combined with Imipramine.
EnclomipheneThe metabolism of Enclomiphene can be decreased when combined with Imipramine.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Imipramine.
EntacaponeThe risk or severity of adverse effects can be increased when Imipramine is combined with Entacapone.
EnzalutamideThe serum concentration of Imipramine can be increased when it is combined with Enzalutamide.
EphedraThe therapeutic efficacy of Ephedra can be decreased when used in combination with Imipramine.
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Imipramine.
EpinephrineThe therapeutic efficacy of Epinephrine can be decreased when used in combination with Imipramine.
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Imipramine is combined with Ergoloid mesylate.
ErgonovineThe serum concentration of Imipramine can be increased when it is combined with Ergonovine.
ErgonovineThe risk or severity of adverse effects can be increased when Imipramine is combined with Ergonovine.
ErgotamineImipramine may increase the vasopressor activities of Ergotamine.
ErgotamineThe serum concentration of Imipramine can be increased when it is combined with Ergotamine.
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Imipramine.
ErythromycinImipramine may increase the QTc-prolonging activities of Erythromycin.
ErythromycinThe metabolism of Imipramine can be decreased when combined with Erythromycin.
EscitalopramThe risk or severity of adverse effects can be increased when Imipramine is combined with Escitalopram.
Eslicarbazepine acetateThe serum concentration of Imipramine can be decreased when it is combined with Eslicarbazepine acetate.
EsmirtazapineThe metabolism of Esmirtazapine can be decreased when combined with Imipramine.
EsomeprazoleThe metabolism of Imipramine can be decreased when combined with Esomeprazole.
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Imipramine.
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Imipramine.
EstramustineThe serum concentration of Imipramine can be increased when it is combined with Estramustine.
EstriolThe serum concentration of Imipramine can be decreased when it is combined with Estriol.
EstriolThe serum concentration of Estriol can be increased when it is combined with Imipramine.
EstroneThe serum concentration of Imipramine can be decreased when it is combined with Estrone.
EstroneThe serum concentration of Estrone can be increased when it is combined with Imipramine.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Imipramine.
EthanolImipramine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Imipramine.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Imipramine.
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Imipramine.
EthosuximideThe risk or severity of adverse effects can be increased when Imipramine is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Imipramine is combined with Ethotoin.
Ethyl biscoumacetateImipramine may increase the anticoagulant activities of Ethyl biscoumacetate.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Imipramine.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Imipramine.
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Imipramine.
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Imipramine.
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Imipramine.
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Imipramine.
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Imipramine.
EtomidateThe therapeutic efficacy of Etomidate can be decreased when used in combination with Imipramine.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Imipramine.
EtoperidoneThe risk or severity of adverse effects can be increased when Imipramine is combined with Etoperidone.
EtoposideThe serum concentration of Imipramine can be increased when it is combined with Etoposide.
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Imipramine.
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Imipramine.
EtravirineThe serum concentration of Imipramine can be decreased when it is combined with Etravirine.
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Imipramine.
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Imipramine.
EzogabineThe risk or severity of adverse effects can be increased when Imipramine is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Imipramine is combined with Felbamate.
FelodipineThe serum concentration of Imipramine can be increased when it is combined with Felodipine.
FencamfamineThe risk or severity of adverse effects can be increased when Imipramine is combined with Fencamfamine.
FenfluramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Fenfluramine.
FenoterolThe risk or severity of adverse effects can be increased when Imipramine is combined with Fenoterol.
FentanylThe serum concentration of Imipramine can be increased when it is combined with Fentanyl.
FentanylThe risk or severity of adverse effects can be increased when Imipramine is combined with Fentanyl.
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Imipramine.
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Imipramine.
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Imipramine.
FingolimodThe metabolism of Fingolimod can be decreased when combined with Imipramine.
FlecainideImipramine may increase the QTc-prolonging activities of Flecainide.
FlibanserinThe risk or severity of adverse effects can be increased when Imipramine is combined with Flibanserin.
FluconazoleThe metabolism of Imipramine can be decreased when combined with Fluconazole.
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Imipramine.
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Imipramine.
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Imipramine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Imipramine.
FluoxetineThe risk or severity of adverse effects can be increased when Imipramine is combined with Fluoxetine.
FluoxetineThe serum concentration of Imipramine can be increased when it is combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Imipramine is combined with Flupentixol.
FlupentixolThe serum concentration of Imipramine can be increased when it is combined with Flupentixol.
FluphenazineThe risk or severity of adverse effects can be increased when Imipramine is combined with Fluphenazine.
FluphenazineThe serum concentration of Imipramine can be increased when it is combined with Fluphenazine.
FlurazepamThe serum concentration of Imipramine can be increased when it is combined with Flurazepam.
FlurazepamThe risk or severity of adverse effects can be increased when Imipramine is combined with Flurazepam.
FluspirileneThe risk or severity of adverse effects can be increased when Imipramine is combined with Fluspirilene.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Imipramine.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Imipramine is combined with Fluticasone Propionate.
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Imipramine.
FluvoxamineThe risk or severity of adverse effects can be increased when Imipramine is combined with Fluvoxamine.
FluvoxamineThe metabolism of Imipramine can be decreased when combined with Fluvoxamine.
FormoterolThe risk or severity of adverse effects can be increased when Imipramine is combined with Formoterol.
FosamprenavirThe serum concentration of Imipramine can be increased when it is combined with Fosamprenavir.
FosaprepitantThe serum concentration of Imipramine can be increased when it is combined with Fosaprepitant.
FosinoprilThe serum concentration of Imipramine can be increased when it is combined with Fosinopril.
FosphenytoinThe risk or severity of adverse effects can be increased when Imipramine is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Imipramine.
FrovatriptanThe risk or severity of adverse effects can be increased when Imipramine is combined with Frovatriptan.
FurazolidoneFurazolidone may increase the serotonergic activities of Imipramine.
Fusidic AcidThe serum concentration of Imipramine can be increased when it is combined with Fusidic Acid.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Imipramine.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Imipramine is combined with gabapentin enacarbil.
Gadobenic acidImipramine may increase the QTc-prolonging activities of Gadobenic acid.
GalantamineThe metabolism of Galantamine can be decreased when combined with Imipramine.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Imipramine.
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Imipramine.
GeldanamycinThe serum concentration of Imipramine can be increased when it is combined with Geldanamycin.
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Imipramine.
GemfibrozilThe metabolism of Imipramine can be decreased when combined with Gemfibrozil.
GemifloxacinImipramine may increase the QTc-prolonging activities of Gemifloxacin.
GenisteinThe serum concentration of Imipramine can be increased when it is combined with Genistein.
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Imipramine.
GlyburideThe serum concentration of Imipramine can be increased when it is combined with Glyburide.
GlycerolThe serum concentration of Imipramine can be increased when it is combined with Glycerol.
GM6001The serum concentration of Imipramine can be increased when it is combined with GM6001.
GoserelinImipramine may increase the QTc-prolonging activities of Goserelin.
Gramicidin DThe serum concentration of Imipramine can be increased when it is combined with Gramicidin D.
GranisetronImipramine may increase the QTc-prolonging activities of Granisetron.
GranisetronGranisetron may increase the serotonergic activities of Imipramine.
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Imipramine.
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Imipramine.
GuanabenzThe therapeutic efficacy of Guanabenz can be decreased when used in combination with Imipramine.
GuanfacineThe therapeutic efficacy of Guanfacine can be decreased when used in combination with Imipramine.
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Imipramine.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Imipramine.
HalofantrineThe metabolism of Halofantrine can be decreased when combined with Imipramine.
HaloperidolThe risk or severity of adverse effects can be increased when Imipramine is combined with Haloperidol.
HaloperidolThe serum concentration of Imipramine can be increased when it is combined with Haloperidol.
HalothaneThe metabolism of Halothane can be decreased when combined with Imipramine.
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Imipramine.
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Imipramine.
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Imipramine.
HirulogThe serum concentration of Imipramine can be increased when it is combined with Hirulog.
HydracarbazineHydracarbazine may increase the serotonergic activities of Imipramine.
HydrocodoneThe metabolism of Hydrocodone can be decreased when combined with Imipramine.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Imipramine.
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Imipramine.
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Imipramine.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Imipramine.
Hydroxyamphetamine hydrobromideImipramine may increase the stimulatory activities of Hydroxyamphetamine hydrobromide.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Imipramine.
HydroxyzineThe risk or severity of adverse effects can be increased when Imipramine is combined with Hydroxyzine.
IbrutinibThe metabolism of Ibrutinib can be decreased when combined with Imipramine.
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Imipramine.
IbutilideImipramine may increase the QTc-prolonging activities of Ibutilide.
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Imipramine.
IdelalisibThe serum concentration of Imipramine can be increased when it is combined with Idelalisib.
IloperidoneThe risk or severity of adverse effects can be increased when Imipramine is combined with Iloperidone.
ImatinibThe metabolism of Imipramine can be decreased when combined with Imatinib.
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Imipramine.
IndacaterolThe risk or severity of adverse effects can be increased when Imipramine is combined with Indacaterol.
IndalpineThe risk or severity of adverse effects can be increased when Imipramine is combined with Indalpine.
IndinavirThe serum concentration of Imipramine can be increased when it is combined with Indinavir.
IndomethacinThe serum concentration of Imipramine can be increased when it is combined with Indomethacin.
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Imipramine.
IproclozideIproclozide may increase the serotonergic activities of Imipramine.
IproniazidIproniazid may increase the serotonergic activities of Imipramine.
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Imipramine.
IsavuconazoniumThe metabolism of Imipramine can be decreased when combined with Isavuconazonium.
IsocarboxazidIsocarboxazid may increase the serotonergic activities of Imipramine.
IsocarboxazidThe risk or severity of adverse effects can be increased when Imipramine is combined with Isocarboxazid.
IsoetarineThe risk or severity of adverse effects can be increased when Imipramine is combined with Isoetarine.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Imipramine.
IsoflurophateThe serum concentration of Imipramine can be increased when it is combined with Isoflurophate.
IsoniazidThe metabolism of Imipramine can be decreased when combined with Isoniazid.
IsoprenalineThe risk or severity of adverse effects can be increased when Imipramine is combined with Isoprenaline.
IsradipineThe metabolism of Imipramine can be decreased when combined with Isradipine.
ItraconazoleThe serum concentration of Imipramine can be increased when it is combined with Itraconazole.
IvacaftorThe serum concentration of Imipramine can be increased when it is combined with Ivacaftor.
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Imipramine.
IxazomibThe serum concentration of Imipramine can be increased when it is combined with Ixazomib.
IxazomibThe metabolism of Ixazomib can be decreased when combined with Imipramine.
KetamineThe serum concentration of Imipramine can be increased when it is combined with Ketamine.
KetamineThe risk or severity of adverse effects can be increased when Imipramine is combined with Ketamine.
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Imipramine.
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Imipramine.
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Imipramine.
KetoconazoleThe serum concentration of Imipramine can be increased when it is combined with Ketoconazole.
LabetalolThe metabolism of Labetalol can be decreased when combined with Imipramine.
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Imipramine.
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Imipramine.
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Imipramine.
LansoprazoleThe serum concentration of Imipramine can be increased when it is combined with Lansoprazole.
LapatinibThe serum concentration of Imipramine can be increased when it is combined with Lapatinib.
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Imipramine.
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Imipramine.
LenvatinibImipramine may increase the QTc-prolonging activities of Lenvatinib.
LepirudinThe serum concentration of Imipramine can be increased when it is combined with Lepirudin.
LeuprolideImipramine may increase the QTc-prolonging activities of Leuprolide.
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Imipramine.
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Imipramine.
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Imipramine.
LevocabastineThe risk or severity of adverse effects can be increased when Imipramine is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Imipramine is combined with Levocetirizine.
LevodopaThe metabolism of Levodopa can be decreased when combined with Imipramine.
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Imipramine.
LevofloxacinImipramine may increase the QTc-prolonging activities of Levofloxacin.
LevofloxacinThe serum concentration of Imipramine can be increased when it is combined with Levofloxacin.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Imipramine.
LevomilnacipranThe risk or severity of adverse effects can be increased when Imipramine is combined with Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Imipramine.
LevothyroxineLevothyroxine may increase the arrhythmogenic activities of Imipramine.
LidocaineThe serum concentration of Imipramine can be increased when it is combined with Lidocaine.
LidocaineThe metabolism of Lidocaine can be decreased when combined with Imipramine.
LinagliptinThe serum concentration of Imipramine can be increased when it is combined with Linagliptin.
LinezolidLinezolid may increase the serotonergic activities of Imipramine.
LinezolidThe risk or severity of adverse effects can be increased when Imipramine is combined with Linezolid.
LiothyronineLiothyronine may increase the arrhythmogenic activities of Imipramine.
LiotrixLiotrix may increase the arrhythmogenic activities of Imipramine.
LisdexamfetamineImipramine may increase the stimulatory activities of Lisdexamfetamine.
LisinoprilThe serum concentration of Imipramine can be increased when it is combined with Lisinopril.
LisurideThe metabolism of Lisuride can be decreased when combined with Imipramine.
LithiumThe risk or severity of adverse effects can be increased when Imipramine is combined with Lithium.
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Imipramine.
LofexidineThe therapeutic efficacy of Lofexidine can be decreased when used in combination with Imipramine.
LomitapideThe serum concentration of Imipramine can be increased when it is combined with Lomitapide.
LomustineThe metabolism of Lomustine can be decreased when combined with Imipramine.
LoperamideThe serum concentration of Imipramine can be increased when it is combined with Loperamide.
LopinavirThe serum concentration of Imipramine can be increased when it is combined with Lopinavir.
LopinavirImipramine may increase the QTc-prolonging activities of Lopinavir.
LoratadineThe serum concentration of Imipramine can be increased when it is combined with Loratadine.
LoratadineThe metabolism of Loratadine can be decreased when combined with Imipramine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Imipramine.
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Imipramine.
LosartanThe serum concentration of Imipramine can be increased when it is combined with Losartan.
LovastatinThe metabolism of Imipramine can be decreased when combined with Lovastatin.
LoxapineThe risk or severity of adverse effects can be increased when Imipramine is combined with Loxapine.
Lu AA21004The risk or severity of adverse effects can be increased when Imipramine is combined with Lu AA21004.
LuliconazoleThe serum concentration of Imipramine can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Imipramine can be decreased when it is combined with Lumacaftor.
LumefantrineImipramine may increase the QTc-prolonging activities of Lumefantrine.
LumefantrineThe metabolism of Imipramine can be decreased when combined with Lumefantrine.
LurasidoneThe risk or severity of adverse effects can be increased when Imipramine is combined with Lurasidone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Imipramine.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Imipramine is combined with Magnesium Sulfate.
MannitolThe serum concentration of Mannitol can be increased when it is combined with Imipramine.
MaprotilineThe serum concentration of Imipramine can be increased when it is combined with Maprotiline.
MaprotilineThe metabolism of Maprotiline can be decreased when combined with Imipramine.
MebanazineMebanazine may increase the serotonergic activities of Imipramine.
MebendazoleThe serum concentration of Imipramine can be increased when it is combined with Mebendazole.
MeclizineThe risk or severity of adverse effects can be increased when Imipramine is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Imipramine.
MefloquineThe serum concentration of Imipramine can be increased when it is combined with Mefloquine.
Megestrol acetateThe serum concentration of Imipramine can be increased when it is combined with Megestrol acetate.
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Imipramine.
MelperoneThe risk or severity of adverse effects can be increased when Imipramine is combined with Melperone.
MephentermineImipramine may increase the stimulatory activities of Mephentermine.
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Imipramine.
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Imipramine.
MeprobamateThe serum concentration of Imipramine can be increased when it is combined with Meprobamate.
MeprobamateThe risk or severity of adverse effects can be increased when Imipramine is combined with Meprobamate.
MequitazineThe metabolism of Mequitazine can be decreased when combined with Imipramine.
MesoridazineThe risk or severity of adverse effects can be increased when Imipramine is combined with Mesoridazine.
MetaraminolImipramine may increase the vasopressor activities of Metaraminol.
MetaxaloneThe risk or severity of adverse effects can be increased when Imipramine is combined with Metaxalone.
MethadoneImipramine may increase the QTc-prolonging activities of Methadone.
MethadoneThe serum concentration of Imipramine can be increased when it is combined with Methadone.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Imipramine.
MethamphetamineImipramine may increase the stimulatory activities of Methamphetamine.
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Imipramine.
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Imipramine.
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Imipramine.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Imipramine.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Imipramine.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Imipramine is combined with Methotrimeprazine.
MethoxamineImipramine may increase the vasopressor activities of Methoxamine.
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Imipramine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Imipramine.
MethsuximideThe risk or severity of adverse effects can be increased when Imipramine is combined with Methsuximide.
Methylene blueImipramine may increase the serotonergic activities of Methylene blue.
MethylphenidateThe risk or severity of adverse effects can be increased when Methylphenidate is combined with Imipramine.
MethylphenidateThe metabolism of Methylphenidate can be decreased when combined with Imipramine.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Imipramine.
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Imipramine.
MethyprylonThe metabolism of Methyprylon can be decreased when combined with Imipramine.
MetoclopramideThe risk or severity of adverse effects can be increased when Imipramine is combined with Metoclopramide.
MetoprololThe serum concentration of Imipramine can be increased when it is combined with Metoprolol.
MetyrosineImipramine may increase the sedative activities of Metyrosine.
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Imipramine.
MexiletineThe metabolism of Imipramine can be decreased when combined with Mexiletine.
MianserinThe metabolism of Mianserin can be decreased when combined with Imipramine.
MibefradilThe serum concentration of Imipramine can be increased when it is combined with Mibefradil.
MiconazoleThe serum concentration of Imipramine can be increased when it is combined with Miconazole.
MidazolamThe serum concentration of Imipramine can be decreased when it is combined with Midazolam.
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Imipramine.
MidodrineImipramine may increase the vasopressor activities of Midodrine.
MifepristoneThe metabolism of Imipramine can be decreased when combined with Mifepristone.
MifepristoneImipramine may increase the QTc-prolonging activities of Mifepristone.
MilnacipranThe risk or severity of adverse effects can be increased when Imipramine is combined with Milnacipran.
MinaprineMinaprine may increase the serotonergic activities of Imipramine.
MinaprineThe metabolism of Minaprine can be decreased when combined with Imipramine.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Imipramine.
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Imipramine.
MirabegronThe metabolism of Imipramine can be decreased when combined with Mirabegron.
MirtazapineImipramine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Imipramine.
MitomycinThe serum concentration of Imipramine can be increased when it is combined with Mitomycin.
MitotaneThe serum concentration of Imipramine can be decreased when it is combined with Mitotane.
MitoxantroneThe serum concentration of Imipramine can be decreased when it is combined with Mitoxantrone.
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Imipramine.
MoclobemideMoclobemide may increase the serotonergic activities of Imipramine.
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Imipramine.
ModafinilThe serum concentration of Imipramine can be decreased when it is combined with Modafinil.
MoexiprilThe serum concentration of Imipramine can be increased when it is combined with Moexipril.
MolindoneThe risk or severity of adverse effects can be increased when Imipramine is combined with Molindone.
MorphineThe serum concentration of Morphine can be increased when it is combined with Imipramine.
MoxifloxacinImipramine may increase the QTc-prolonging activities of Moxifloxacin.
MoxonidineThe therapeutic efficacy of Moxonidine can be decreased when used in combination with Imipramine.
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Imipramine.
N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-ProlineThe serum concentration of Imipramine can be increased when it is combined with N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Imipramine.
NabiloneThe risk or severity of adverse effects can be increased when Imipramine is combined with Nabilone.
NadololThe serum concentration of Nadolol can be increased when it is combined with Imipramine.
NafcillinThe serum concentration of Imipramine can be decreased when it is combined with Nafcillin.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Imipramine.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Imipramine.
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Imipramine.
NaltrexoneThe serum concentration of Imipramine can be increased when it is combined with Naltrexone.
NaphazolineThe therapeutic efficacy of Naphazoline can be decreased when used in combination with Imipramine.
NaratriptanThe risk or severity of adverse effects can be increased when Imipramine is combined with Naratriptan.
NaringeninThe serum concentration of Imipramine can be increased when it is combined with Naringenin.
NateglinideThe metabolism of Nateglinide can be decreased when combined with Imipramine.
NCX 4016The serum concentration of Imipramine can be increased when it is combined with NCX 4016.
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Imipramine.
NefazodoneThe serum concentration of Imipramine can be decreased when it is combined with Nefazodone.
NefazodoneThe metabolism of Nefazodone can be decreased when combined with Imipramine.
NelfinavirThe serum concentration of Imipramine can be increased when it is combined with Nelfinavir.
NeostigmineThe serum concentration of Imipramine can be increased when it is combined with Neostigmine.
NetupitantThe serum concentration of Imipramine can be increased when it is combined with Netupitant.
NetupitantThe metabolism of Netupitant can be decreased when combined with Imipramine.
NevirapineThe metabolism of Imipramine can be decreased when combined with Nevirapine.
NialamideNialamide may increase the serotonergic activities of Imipramine.
NicardipineThe serum concentration of Imipramine can be increased when it is combined with Nicardipine.
NicergolineThe metabolism of Nicergoline can be decreased when combined with Imipramine.
NicorandilImipramine may increase the hypotensive activities of Nicorandil.
NicotineThe metabolism of Nicotine can be decreased when combined with Imipramine.
NifedipineThe serum concentration of Imipramine can be decreased when it is combined with Nifedipine.
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Imipramine.
NilotinibThe metabolism of Imipramine can be decreased when combined with Nilotinib.
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Imipramine.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Imipramine.
NisoldipineThe serum concentration of Imipramine can be increased when it is combined with Nisoldipine.
NitrazepamThe serum concentration of Imipramine can be increased when it is combined with Nitrazepam.
NitrazepamThe risk or severity of adverse effects can be increased when Imipramine is combined with Nitrazepam.
NitrendipineThe serum concentration of Imipramine can be increased when it is combined with Nitrendipine.
NitrofuralThe metabolism of Nitrofural can be decreased when combined with Imipramine.
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Imipramine.
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Imipramine.
NorepinephrineThe therapeutic efficacy of Norepinephrine can be decreased when used in combination with Imipramine.
NorethisteroneThe serum concentration of Imipramine can be decreased when it is combined with Norethisterone.
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Imipramine.
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Imipramine.
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Imipramine.
OctamoxinOctamoxin may increase the serotonergic activities of Imipramine.
OfloxacinImipramine may increase the QTc-prolonging activities of Ofloxacin.
OlanzapineThe risk or severity of adverse effects can be increased when Imipramine is combined with Olanzapine.
OlaparibThe metabolism of Imipramine can be decreased when combined with Olaparib.
OlodaterolThe risk or severity of adverse effects can be increased when Imipramine is combined with Olodaterol.
OlopatadineThe risk or severity of adverse effects can be increased when Imipramine is combined with Olopatadine.
OmapatrilatThe serum concentration of Imipramine can be increased when it is combined with Omapatrilat.
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Imipramine.
OmeprazoleThe serum concentration of Imipramine can be increased when it is combined with Omeprazole.
OndansetronThe risk or severity of adverse effects can be increased when Imipramine is combined with Ondansetron.
OndansetronOndansetron may increase the serotonergic activities of Imipramine.
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Imipramine.
OrciprenalineThe risk or severity of adverse effects can be increased when Imipramine is combined with Orciprenaline.
OrphenadrineImipramine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Imipramine.
OsanetantThe risk or severity of adverse effects can be increased when Imipramine is combined with Osanetant.
OsimertinibThe serum concentration of Imipramine can be increased when it is combined with Osimertinib.
OtamixabanThe serum concentration of Imipramine can be increased when it is combined with Otamixaban.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Imipramine.
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Imipramine.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Imipramine.
OxycodoneThe metabolism of Oxycodone can be decreased when combined with Imipramine.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Imipramine.
OxymetazolineThe therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Imipramine.
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Imipramine.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Imipramine.
P-NitrophenolThe serum concentration of Imipramine can be increased when it is combined with P-Nitrophenol.
PaclitaxelThe serum concentration of Imipramine can be increased when it is combined with Paclitaxel.
PalbociclibThe serum concentration of Imipramine can be increased when it is combined with Palbociclib.
PaliperidoneThe therapeutic efficacy of Paliperidone can be decreased when used in combination with Imipramine.
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Imipramine.
Palmitic AcidThe serum concentration of Imipramine can be increased when it is combined with Palmitic Acid.
PalonosetronPalonosetron may increase the serotonergic activities of Imipramine.
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Imipramine.
PanobinostatImipramine may increase the QTc-prolonging activities of Panobinostat.
PanobinostatThe metabolism of Imipramine can be decreased when combined with Panobinostat.
PantoprazoleThe serum concentration of Imipramine can be increased when it is combined with Pantoprazole.
ParaldehydeImipramine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Imipramine.
PargylinePargyline may increase the serotonergic activities of Imipramine.
ParoxetineThe risk or severity of adverse effects can be increased when Imipramine is combined with Paroxetine.
ParoxetineThe serum concentration of Imipramine can be increased when it is combined with Paroxetine.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Imipramine.
Peginterferon alfa-2bThe serum concentration of Imipramine can be decreased when it is combined with Peginterferon alfa-2b.
PentamidineImipramine may increase the QTc-prolonging activities of Pentamidine.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Imipramine.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Imipramine.
PerampanelThe risk or severity of adverse effects can be increased when Imipramine is combined with Perampanel.
PerflutrenImipramine may increase the QTc-prolonging activities of Perflutren.
PergolideThe therapeutic efficacy of Pergolide can be decreased when used in combination with Imipramine.
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Imipramine.
PerindoprilThe serum concentration of Imipramine can be increased when it is combined with Perindopril.
PerospironeThe risk or severity of adverse effects can be increased when Imipramine is combined with Perospirone.
PerphenazineThe risk or severity of adverse effects can be increased when Imipramine is combined with Perphenazine.
PethidineThe metabolism of Pethidine can be decreased when combined with Imipramine.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Imipramine.
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Imipramine.
PhenelzinePhenelzine may increase the serotonergic activities of Imipramine.
PhenelzineThe risk or severity of adverse effects can be increased when Imipramine is combined with Phenelzine.
PhenforminThe metabolism of Phenformin can be decreased when combined with Imipramine.
PhenindioneImipramine may increase the anticoagulant activities of Phenindione.
PheniprazinePheniprazine may increase the serotonergic activities of Imipramine.
PhenobarbitalThe serum concentration of Imipramine can be decreased when it is combined with Phenobarbital.
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Imipramine.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Imipramine.
PhenoxypropazinePhenoxypropazine may increase the serotonergic activities of Imipramine.
PhenprocoumonImipramine may increase the anticoagulant activities of Phenprocoumon.
PhentermineImipramine may increase the stimulatory activities of Phentermine.
PhenylephrineImipramine may increase the vasopressor activities of Phenylephrine.
PhenylpropanolamineThe therapeutic efficacy of Phenylpropanolamine can be decreased when used in combination with Imipramine.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Imipramine.
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Imipramine.
PhosphoramidonThe serum concentration of Imipramine can be increased when it is combined with Phosphoramidon.
PimozideThe risk or severity of adverse effects can be increased when Imipramine is combined with Pimozide.
PimozideThe serum concentration of Imipramine can be increased when it is combined with Pimozide.
PindololThe metabolism of Pindolol can be decreased when combined with Imipramine.
PipamperoneThe risk or severity of adverse effects can be increased when Imipramine is combined with Pipamperone.
PiperazineThe metabolism of Piperazine can be decreased when combined with Imipramine.
PipotiazineThe risk or severity of adverse effects can be increased when Imipramine is combined with Pipotiazine.
PirbuterolThe risk or severity of adverse effects can be increased when Imipramine is combined with Pirbuterol.
PirlindolePirlindole may increase the serotonergic activities of Imipramine.
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Imipramine.
PivhydrazinePivhydrazine may increase the serotonergic activities of Imipramine.
PizotifenThe risk or severity of adverse effects can be increased when Imipramine is combined with Pizotifen.
Platelet Activating FactorThe serum concentration of Imipramine can be decreased when it is combined with Platelet Activating Factor.
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Imipramine.
PomalidomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Imipramine.
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Imipramine.
PosaconazoleThe serum concentration of Imipramine can be increased when it is combined with Posaconazole.
PramipexoleImipramine may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Imipramine.
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Imipramine.
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Imipramine.
PrazosinThe serum concentration of Imipramine can be increased when it is combined with Prazosin.
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Imipramine.
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Imipramine.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Imipramine.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Imipramine.
PrimaquineImipramine may increase the QTc-prolonging activities of Primaquine.
PrimidoneThe risk or severity of adverse effects can be increased when Imipramine is combined with Primidone.
PrinomastatThe serum concentration of Imipramine can be increased when it is combined with Prinomastat.
ProbenecidThe serum concentration of Imipramine can be increased when it is combined with Probenecid.
ProcainamideThe metabolism of Procainamide can be decreased when combined with Imipramine.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Imipramine.
ProcarbazineThe risk or severity of adverse effects can be increased when Imipramine is combined with Procarbazine.
ProcaterolThe risk or severity of adverse effects can be increased when Imipramine is combined with Procaterol.
ProchlorperazineThe risk or severity of adverse effects can be increased when Imipramine is combined with Prochlorperazine.
ProgesteroneThe serum concentration of Imipramine can be decreased when it is combined with Progesterone.
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Imipramine.
PromazineThe risk or severity of adverse effects can be increased when Imipramine is combined with Promazine.
PromazineThe metabolism of Imipramine can be decreased when combined with Promazine.
PromethazineThe serum concentration of Imipramine can be increased when it is combined with Promethazine.
PromethazineThe metabolism of Promethazine can be decreased when combined with Imipramine.
PropafenoneThe serum concentration of Imipramine can be increased when it is combined with Propafenone.
PropafenoneImipramine may increase the QTc-prolonging activities of Propafenone.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Imipramine.
PropericiazineThe risk or severity of adverse effects can be increased when Imipramine is combined with Propericiazine.
PropofolThe metabolism of Propofol can be decreased when combined with Imipramine.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Imipramine.
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Imipramine.
PropranololThe serum concentration of Propranolol can be increased when it is combined with Imipramine.
ProtriptylineThe serum concentration of Imipramine can be increased when it is combined with Protriptyline.
ProtriptylineThe metabolism of Protriptyline can be decreased when combined with Imipramine.
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Imipramine.
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Imipramine.
PseudoephedrineThe therapeutic efficacy of Pseudoephedrine can be decreased when used in combination with Imipramine.
QuazepamThe serum concentration of Imipramine can be increased when it is combined with Quazepam.
QuazepamThe risk or severity of adverse effects can be increased when Imipramine is combined with Quazepam.
QuercetinThe serum concentration of Imipramine can be increased when it is combined with Quercetin.
QuetiapineThe risk or severity of adverse effects can be increased when Imipramine is combined with Quetiapine.
QuinacrineThe serum concentration of Imipramine can be increased when it is combined with Quinacrine.
QuinaprilThe serum concentration of Imipramine can be increased when it is combined with Quinapril.
QuinidineThe serum concentration of Imipramine can be increased when it is combined with Quinidine.
QuinineThe serum concentration of Imipramine can be increased when it is combined with Quinine.
RamelteonThe risk or severity of adverse effects can be increased when Imipramine is combined with Ramelteon.
RamiprilThe serum concentration of Imipramine can be increased when it is combined with Ramipril.
RanitidineThe serum concentration of Imipramine can be increased when it is combined with Ranitidine.
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Imipramine.
RasagilineRasagiline may increase the serotonergic activities of Imipramine.
RasagilineThe risk or severity of adverse effects can be increased when Imipramine is combined with Rasagiline.
ReboxetineThe serum concentration of Imipramine can be increased when it is combined with Reboxetine.
RegorafenibThe serum concentration of Imipramine can be increased when it is combined with Regorafenib.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Imipramine.
RemikirenThe serum concentration of Imipramine can be increased when it is combined with Remikiren.
RemoxiprideThe risk or severity of adverse effects can be increased when Imipramine is combined with Remoxipride.
repinotanThe metabolism of repinotan can be decreased when combined with Imipramine.
ReserpineThe risk or severity of adverse effects can be increased when Imipramine is combined with Reserpine.
ReserpineThe serum concentration of Imipramine can be decreased when it is combined with Reserpine.
RifabutinThe metabolism of Imipramine can be increased when combined with Rifabutin.
RifampicinThe serum concentration of Imipramine can be decreased when it is combined with Rifampicin.
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Imipramine.
RifapentineThe metabolism of Imipramine can be increased when combined with Rifapentine.
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Imipramine.
RilpivirineThe serum concentration of Imipramine can be increased when it is combined with Rilpivirine.
RisperidoneThe therapeutic efficacy of Risperidone can be decreased when used in combination with Imipramine.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Imipramine.
RitodrineThe risk or severity of adverse effects can be increased when Imipramine is combined with Ritodrine.
RitonavirThe serum concentration of Imipramine can be increased when it is combined with Ritonavir.
RivaroxabanThe serum concentration of Imipramine can be increased when it is combined with Rivaroxaban.
RizatriptanThe risk or severity of adverse effects can be increased when Imipramine is combined with Rizatriptan.
RolapitantThe serum concentration of Imipramine can be increased when it is combined with Rolapitant.
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Imipramine.
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Imipramine.
RopiniroleImipramine may increase the sedative activities of Ropinirole.
RopiniroleThe metabolism of Imipramine can be decreased when combined with Ropinirole.
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Imipramine.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Imipramine.
RotigotineImipramine may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Imipramine.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Imipramine.
SafrazineSafrazine may increase the serotonergic activities of Imipramine.
SalbutamolThe risk or severity of adverse effects can be increased when Imipramine is combined with Salbutamol.
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Imipramine.
SalmeterolThe risk or severity of adverse effects can be increased when Imipramine is combined with Salmeterol.
SaquinavirThe serum concentration of Imipramine can be increased when it is combined with Saquinavir.
SaquinavirImipramine may increase the QTc-prolonging activities of Saquinavir.
SaxagliptinThe serum concentration of Imipramine can be increased when it is combined with Saxagliptin.
ScopolamineThe serum concentration of Imipramine can be increased when it is combined with Scopolamine.
ScopolamineThe risk or severity of adverse effects can be increased when Imipramine is combined with Scopolamine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Imipramine.
SelegilineSelegiline may increase the serotonergic activities of Imipramine.
SelegilineThe risk or severity of adverse effects can be increased when Imipramine is combined with Selegiline.
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Imipramine.
SertindoleThe risk or severity of adverse effects can be increased when Imipramine is combined with Sertindole.
SertralineThe risk or severity of adverse effects can be increased when Imipramine is combined with Sertraline.
SertralineThe serum concentration of Imipramine can be increased when it is combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Imipramine.
SildenafilThe metabolism of Imipramine can be decreased when combined with Sildenafil.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Imipramine.
SiltuximabThe serum concentration of Imipramine can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Imipramine can be increased when it is combined with Simeprevir.
SimvastatinThe serum concentration of Imipramine can be increased when it is combined with Simvastatin.
SimvastatinThe metabolism of Simvastatin can be decreased when combined with Imipramine.
SirolimusThe serum concentration of Imipramine can be decreased when it is combined with Sirolimus.
SitagliptinThe serum concentration of Imipramine can be increased when it is combined with Sitagliptin.
Sodium oxybateThe risk or severity of adverse effects can be increased when Sodium oxybate is combined with Imipramine.
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Imipramine.
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Imipramine.
SotalolImipramine may increase the QTc-prolonging activities of Sotalol.
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Imipramine.
SparteineThe metabolism of Sparteine can be decreased when combined with Imipramine.
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Imipramine.
SpiraprilThe serum concentration of Imipramine can be increased when it is combined with Spirapril.
SpironolactoneThe serum concentration of Imipramine can be increased when it is combined with Spironolactone.
St. John's WortThe serum concentration of Imipramine can be decreased when it is combined with St. John's Wort.
StaurosporineThe serum concentration of Imipramine can be increased when it is combined with Staurosporine.
StiripentolThe risk or severity of adverse effects can be increased when Imipramine is combined with Stiripentol.
StreptozocinThe serum concentration of Imipramine can be decreased when it is combined with Streptozocin.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Imipramine.
SulfinpyrazoneThe serum concentration of Imipramine can be increased when it is combined with Sulfinpyrazone.
SulfisoxazoleImipramine may increase the QTc-prolonging activities of Sulfisoxazole.
SulfisoxazoleThe metabolism of Imipramine can be decreased when combined with Sulfisoxazole.
SulpirideThe risk or severity of adverse effects can be increased when Imipramine is combined with Sulpiride.
SumatriptanThe serum concentration of Imipramine can be increased when it is combined with Sumatriptan.
SumatriptanThe risk or severity of adverse effects can be increased when Imipramine is combined with Sumatriptan.
SunitinibThe serum concentration of Imipramine can be increased when it is combined with Sunitinib.
SuvorexantThe risk or severity of adverse effects can be increased when Imipramine is combined with Suvorexant.
TacrineThe serum concentration of Imipramine can be increased when it is combined with Tacrine.
TacrolimusThe serum concentration of Imipramine can be decreased when it is combined with Tacrolimus.
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Imipramine.
TamoxifenThe serum concentration of Imipramine can be decreased when it is combined with Tamoxifen.
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Imipramine.
TamsulosinThe metabolism of Tamsulosin can be decreased when combined with Imipramine.
TapentadolThe metabolism of Tapentadol can be decreased when combined with Imipramine.
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Imipramine.
TasimelteonThe risk or severity of adverse effects can be increased when Imipramine is combined with Tasimelteon.
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Imipramine.
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Imipramine.
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Imipramine.
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Imipramine is combined with Tedizolid Phosphate.
TegaserodThe metabolism of Tegaserod can be decreased when combined with Imipramine.
TelaprevirThe serum concentration of Imipramine can be increased when it is combined with Telaprevir.
TelavancinImipramine may increase the QTc-prolonging activities of Telavancin.
TelithromycinImipramine may increase the QTc-prolonging activities of Telithromycin.
TelithromycinThe metabolism of Imipramine can be decreased when combined with Telithromycin.
TelmisartanThe serum concentration of Imipramine can be increased when it is combined with Telmisartan.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Imipramine.
TemocaprilThe serum concentration of Imipramine can be increased when it is combined with Temocapril.
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Imipramine.
TenofovirThe metabolism of Imipramine can be decreased when combined with Tenofovir.
TerazosinThe serum concentration of Imipramine can be increased when it is combined with Terazosin.
TerbinafineThe metabolism of Imipramine can be decreased when combined with Terbinafine.
TerbutalineThe risk or severity of adverse effects can be increased when Imipramine is combined with Terbutaline.
TerfenadineThe serum concentration of Imipramine can be increased when it is combined with Terfenadine.
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Imipramine.
TeriflunomideThe serum concentration of Imipramine can be decreased when it is combined with Teriflunomide.
TesmilifeneThe serum concentration of Imipramine can be decreased when it is combined with Tesmilifene.
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Imipramine.
TestosteroneThe serum concentration of Imipramine can be increased when it is combined with Testosterone.
TetrabenazineThe metabolism of Tetrabenazine can be decreased when combined with Imipramine.
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Imipramine.
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Imipramine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Imipramine.
ThalidomideImipramine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Imipramine.
TheophyllineThe metabolism of Imipramine can be decreased when combined with Theophylline.
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Imipramine.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Imipramine.
ThioproperazineThe risk or severity of adverse effects can be increased when Imipramine is combined with Thioproperazine.
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Imipramine.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Imipramine.
ThiorphanThe serum concentration of Imipramine can be increased when it is combined with Thiorphan.
ThiotepaThe metabolism of Imipramine can be decreased when combined with Thiotepa.
ThiothixeneThe risk or severity of adverse effects can be increased when Imipramine is combined with Thiothixene.
Thyroid, porcineThyroid, porcine may increase the arrhythmogenic activities of Imipramine.
TiagabineThe risk or severity of adverse effects can be increased when Imipramine is combined with Tiagabine.
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Imipramine.
TiclopidineThe metabolism of Imipramine can be decreased when combined with Ticlopidine.
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Imipramine.
TimololThe serum concentration of Timolol can be increased when it is combined with Imipramine.
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Imipramine.
TipranavirThe serum concentration of Imipramine can be increased when it is combined with Tipranavir.
TipranavirThe metabolism of Tipranavir can be decreased when combined with Imipramine.
TizanidineThe therapeutic efficacy of Tizanidine can be decreased when used in combination with Imipramine.
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Imipramine.
TocilizumabThe serum concentration of Imipramine can be decreased when it is combined with Tocilizumab.
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Imipramine.
ToloxatoneToloxatone may increase the serotonergic activities of Imipramine.
TolterodineThe metabolism of Tolterodine can be decreased when combined with Imipramine.
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Imipramine.
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Imipramine.
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Imipramine.
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Imipramine.
TrabectedinThe metabolism of Trabectedin can be decreased when combined with Imipramine.
TramadolThe therapeutic efficacy of Tramadol can be decreased when used in combination with Imipramine.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Imipramine.
TrandolaprilThe serum concentration of Imipramine can be increased when it is combined with Trandolapril.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the serotonergic activities of Imipramine.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Imipramine is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineTranylcypromine may increase the serotonergic activities of Imipramine.
TranylcypromineThe risk or severity of adverse effects can be increased when Imipramine is combined with Tranylcypromine.
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Imipramine.
TrazodoneThe risk or severity of adverse effects can be increased when Imipramine is combined with Trazodone.
TrazodoneThe serum concentration of Imipramine can be decreased when it is combined with Trazodone.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Imipramine.
TrifluoperazineThe risk or severity of adverse effects can be increased when Imipramine is combined with Trifluoperazine.
TrifluoperazineThe serum concentration of Imipramine can be increased when it is combined with Trifluoperazine.
TriflupromazineThe risk or severity of adverse effects can be increased when Imipramine is combined with Triflupromazine.
TriflupromazineThe serum concentration of Imipramine can be increased when it is combined with Triflupromazine.
TrimethoprimThe serum concentration of Imipramine can be decreased when it is combined with Trimethoprim.
TrimipramineThe serum concentration of Imipramine can be increased when it is combined with Trimipramine.
TrimipramineThe metabolism of Trimipramine can be decreased when combined with Imipramine.
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Imipramine.
TroleandomycinThe serum concentration of Imipramine can be increased when it is combined with Troleandomycin.
UbenimexThe serum concentration of Imipramine can be increased when it is combined with Ubenimex.
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Imipramine.
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Imipramine.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Imipramine.
VandetanibImipramine may increase the QTc-prolonging activities of Vandetanib.
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Imipramine.
VemurafenibThe serum concentration of Imipramine can be increased when it is combined with Vemurafenib.
VemurafenibImipramine may increase the QTc-prolonging activities of Vemurafenib.
VenlafaxineThe metabolism of Imipramine can be decreased when combined with Venlafaxine.
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Imipramine.
VerapamilThe metabolism of Imipramine can be decreased when combined with Verapamil.
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Imipramine.
VigabatrinThe risk or severity of adverse effects can be increased when Imipramine is combined with Vigabatrin.
VilanterolThe risk or severity of adverse effects can be increased when Imipramine is combined with Vilanterol.
VilazodoneThe risk or severity of adverse effects can be increased when Imipramine is combined with Vilazodone.
VildagliptinThe serum concentration of Imipramine can be increased when it is combined with Vildagliptin.
VinblastineThe serum concentration of Imipramine can be decreased when it is combined with Vinblastine.
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Imipramine.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Imipramine.
VincristineThe serum concentration of Imipramine can be decreased when it is combined with Vincristine.
VinorelbineThe serum concentration of Imipramine can be increased when it is combined with Vinorelbine.
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Imipramine.
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Imipramine.
VoriconazoleThe metabolism of Imipramine can be decreased when combined with Voriconazole.
VortioxetineThe risk or severity of adverse effects can be increased when Imipramine is combined with Vortioxetine.
WarfarinImipramine may increase the anticoagulant activities of Warfarin.
XimelagatranThe serum concentration of Imipramine can be increased when it is combined with Ximelagatran.
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Imipramine.
XylometazolineThe therapeutic efficacy of Xylometazoline can be decreased when used in combination with Imipramine.
YohimbineThe serum concentration of Yohimbine can be increased when it is combined with Imipramine.
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Imipramine.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Imipramine.
ZiconotideThe risk or severity of adverse effects can be increased when Imipramine is combined with Ziconotide.
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Imipramine.
ZimelidineThe risk or severity of adverse effects can be increased when Imipramine is combined with Zimelidine.
ZimelidineThe serum concentration of Imipramine can be increased when it is combined with Zimelidine.
ZiprasidoneThe risk or severity of adverse effects can be increased when Imipramine is combined with Ziprasidone.
ZiprasidoneThe metabolism of Imipramine can be decreased when combined with Ziprasidone.
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Imipramine.
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Imipramine.
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Imipramine.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Imipramine.
ZonisamideThe risk or severity of adverse effects can be increased when Imipramine is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Imipramine.
ZotepineThe risk or severity of adverse effects can be increased when Imipramine is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Imipramine is combined with Zuclopenthixol.
Food Interactions
  • Avoid alcohol.
  • Avoid excessive quantities of coffee or tea (caffeine).
  • Avoid St.John's Wort.
  • Do not take fibers at the same time.
  • Take with food.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Norepinephrine:sodium symporter activity
Specific Function:
Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name:
SLC6A2
Uniprot ID:
P23975
Molecular Weight:
69331.42 Da
References
  1. Mitchell HA, Ahern TH, Liles LC, Javors MA, Weinshenker D: The effects of norepinephrine transporter inactivation on locomotor activity in mice. Biol Psychiatry. 2006 Nov 15;60(10):1046-52. Epub 2006 Aug 7. [PubMed:16893531 ]
  2. Dziedzicka-Wasylewska M, Faron-Gorecka A, Kusmider M, Drozdowska E, Rogoz Z, Siwanowicz J, Caron MG, Bonisch H: Effect of antidepressant drugs in mice lacking the norepinephrine transporter. Neuropsychopharmacology. 2006 Nov;31(11):2424-32. Epub 2006 Mar 22. [PubMed:16554743 ]
  3. Anton M, Wagner B, Haubner R, Bodenstein C, Essien BE, Bonisch H, Schwaiger M, Gansbacher B, Weber WA: Use of the norepinephrine transporter as a reporter gene for non-invasive imaging of genetically modified cells. J Gene Med. 2004 Jan;6(1):119-26. [PubMed:14716684 ]
  4. Kantor L, Hewlett GH, Park YH, Richardson-Burns SM, Mellon MJ, Gnegy ME: Protein kinase C and intracellular calcium are required for amphetamine-mediated dopamine release via the norepinephrine transporter in undifferentiated PC12 cells. J Pharmacol Exp Ther. 2001 Jun;297(3):1016-24. [PubMed:11356924 ]
  5. Tatsumi M, Jansen K, Blakely RD, Richelson E: Pharmacological profile of neuroleptics at human monoamine transporters. Eur J Pharmacol. 1999 Mar 5;368(2-3):277-83. [PubMed:10193665 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Serotonin:sodium symporter activity
Specific Function:
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into the pre-synaptic terminal for re-utilization. Plays a key role in mediating regulation of the availability of serotonin to other receptors of serotonergic systems. Terminates the action of serotonin an...
Gene Name:
SLC6A4
Uniprot ID:
P31645
Molecular Weight:
70324.165 Da
References
  1. Leboyer M, Quintin P, Manivet P, Varoquaux O, Allilaire JF, Launay JM: Decreased serotonin transporter binding in unaffected relatives of manic depressive patients. Biol Psychiatry. 1999 Dec 15;46(12):1703-6. [PubMed:10624553 ]
  2. Scholze P, Zwach J, Kattinger A, Pifl C, Singer EA, Sitte HH: Transporter-mediated release: a superfusion study on human embryonic kidney cells stably expressing the human serotonin transporter. J Pharmacol Exp Ther. 2000 Jun;293(3):870-8. [PubMed:10869387 ]
  3. Quintin P, Benkelfat C, Launay JM, Arnulf I, Pointereau-Bellenger A, Barbault S, Alvarez JC, Varoquaux O, Perez-Diaz F, Jouvent R, Leboyer M: Clinical and neurochemical effect of acute tryptophan depletion in unaffected relatives of patients with bipolar affective disorder. Biol Psychiatry. 2001 Aug 1;50(3):184-90. [PubMed:11513817 ]
  4. Goulet M, Miller GM, Bendor J, Liu S, Meltzer PC, Madras BK: Non-amines, drugs without an amine nitrogen, potently block serotonin transport: novel antidepressant candidates? Synapse. 2001 Dec 1;42(3):129-40. [PubMed:11746710 ]
  5. Barkan T, Gurwitz D, Levy G, Weizman A, Rehavi M: Biochemical and pharmacological characterization of the serotonin transporter in human peripheral blood lymphocytes. Eur Neuropsychopharmacol. 2004 May;14(3):237-43. [PubMed:15056483 ]
  6. Schloss P, Betz H: Heterogeneity of antidepressant binding sites on the recombinant rat serotonin transporter SERT1. Biochemistry. 1995 Oct 3;34(39):12590-5. [PubMed:7548008 ]
  7. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Virus receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates...
Gene Name:
HTR2A
Uniprot ID:
P28223
Molecular Weight:
52602.58 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
  2. Zanoveli JM, Nogueira RL, Zangrossi H Jr: Chronic imipramine treatment sensitizes 5-HT1A and 5-HT 2 A receptors in the dorsal periaqueductal gray matter: evidence from the elevated T-maze test of anxiety. Behav Pharmacol. 2005 Nov;16(7):543-52. [PubMed:16170231 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Histamine receptor activity
Specific Function:
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamine release from adrenal medulla, as well as mediating neurotransmission in the central nervous system.
Gene Name:
HRH1
Uniprot ID:
P35367
Molecular Weight:
55783.61 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1A
Uniprot ID:
P35348
Molecular Weight:
51486.005 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
  2. Nojimoto FD, Mueller A, Hebeler-Barbosa F, Akinaga J, Lima V, Kiguti LR, Pupo AS: The tricyclic antidepressants amitriptyline, nortriptyline and imipramine are weak antagonists of human and rat alpha1B-adrenoceptors. Neuropharmacology. 2010 Jul-Aug;59(1-2):49-57. doi: 10.1016/j.neuropharm.2010.03.015. Epub 2010 Apr 2. [PubMed:20363235 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Alpha1-adrenergic receptor activity
Specific Function:
This alpha-adrenergic receptor mediates its effect through the influx of extracellular calcium.
Gene Name:
ADRA1D
Uniprot ID:
P25100
Molecular Weight:
60462.205 Da
References
  1. Nojimoto FD, Mueller A, Hebeler-Barbosa F, Akinaga J, Lima V, Kiguti LR, Pupo AS: The tricyclic antidepressants amitriptyline, nortriptyline and imipramine are weak antagonists of human and rat alpha1B-adrenoceptors. Neuropharmacology. 2010 Jul-Aug;59(1-2):49-57. doi: 10.1016/j.neuropharm.2010.03.015. Epub 2010 Apr 2. [PubMed:20363235 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM1
Uniprot ID:
P11229
Molecular Weight:
51420.375 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
G-protein coupled acetylcholine receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is adenylate cyclase inhibition. Signaling promotes phospholipase C activity, leading to the release of inositol trisphosphate (IP3); this then trigge...
Gene Name:
CHRM2
Uniprot ID:
P08172
Molecular Weight:
51714.605 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM3
Uniprot ID:
P20309
Molecular Weight:
66127.445 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Guanyl-nucleotide exchange factor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is inhibition of adenylate cyclase.
Gene Name:
CHRM4
Uniprot ID:
P08173
Molecular Weight:
53048.65 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM5
Uniprot ID:
P08912
Molecular Weight:
60073.205 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
inhibitor
General Function:
Voltage-gated potassium channel activity
Specific Function:
Voltage-gated potassium channel that mediates transmembrane potassium transport in excitable membranes, primarily in the brain. Mediates the major part of the dendritic A-type current I(SA) in brain neurons (By similarity). This current is activated at membrane potentials that are below the threshold for action potentials. It regulates neuronal excitability, prolongs the latency before the firs...
Gene Name:
KCND2
Uniprot ID:
Q9NZV8
Molecular Weight:
70535.825 Da
References
  1. Casis O, Sanchez-Chapula JA: Disopyramide, imipramine, and amitriptyline bind to a common site on the transient outward K+ channel. J Cardiovasc Pharmacol. 1998 Oct;32(4):521-6. [PubMed:9781919 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
inhibitor
General Function:
Metal ion binding
Specific Function:
Pore-forming (alpha) subunit of voltage-gated rapidly inactivating A-type potassium channels. May contribute to I(To) current in heart and I(Sa) current in neurons. Channel properties are modulated by interactions with other alpha subunits and with regulatory subunits.
Gene Name:
KCND3
Uniprot ID:
Q9UK17
Molecular Weight:
73450.53 Da
References
  1. Casis O, Sanchez-Chapula JA: Disopyramide, imipramine, and amitriptyline bind to a common site on the transient outward K+ channel. J Cardiovasc Pharmacol. 1998 Oct;32(4):521-6. [PubMed:9781919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonistbinder
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-iodophenyl-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modul...
Gene Name:
HTR2C
Uniprot ID:
P28335
Molecular Weight:
51820.705 Da
References
  1. Palvimaki EP, Roth BL, Majasuo H, Laakso A, Kuoppamaki M, Syvalahti E, Hietala J: Interactions of selective serotonin reuptake inhibitors with the serotonin 5-HT2c receptor. Psychopharmacology (Berl). 1996 Aug;126(3):234-40. [PubMed:8876023 ]
  2. Roth BL: Multiple serotonin receptors: clinical and experimental aspects. Ann Clin Psychiatry. 1994 Jun;6(2):67-78. [PubMed:7804391 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine (PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1B
Uniprot ID:
P35368
Molecular Weight:
56835.375 Da
References
  1. Nojimoto FD, Mueller A, Hebeler-Barbosa F, Akinaga J, Lima V, Kiguti LR, Pupo AS: The tricyclic antidepressants amitriptyline, nortriptyline and imipramine are weak antagonists of human and rat alpha1B-adrenoceptors. Neuropharmacology. 2010 Jul-Aug;59(1-2):49-57. doi: 10.1016/j.neuropharm.2010.03.015. Epub 2010 Apr 2. [PubMed:20363235 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor is mediated by G proteins that stimulate adenylate cyclase.
Gene Name:
HTR7
Uniprot ID:
P34969
Molecular Weight:
53554.43 Da
References
  1. Lucchelli A, Santagostino-Barbone MG, D'Agostino G, Masoero E, Tonini M: The interaction of antidepressant drugs with enteric 5-HT7 receptors. Naunyn Schmiedebergs Arch Pharmacol. 2000 Sep;362(3):284-9. [PubMed:10997731 ]
  2. Roth BL: Multiple serotonin receptors: clinical and experimental aspects. Ann Clin Psychiatry. 1994 Jun;6(2):67-78. [PubMed:7804391 ]
Kind
Protein group
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Components:
NameUniProt IDDetails
D(1A) dopamine receptorP21728 Details
D(1B) dopamine receptorP21918 Details
References
  1. Toll L, Berzetei-Gurske IP, Polgar WE, Brandt SR, Adapa ID, Rodriguez L, Schwartz RW, Haggart D, O'Brien A, White A, Kennedy JM, Craymer K, Farrington L, Auh JS: Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications. NIDA Res Monogr. 1998 Mar;178:440-66. [PubMed:9686407 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Potassium channel regulator activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name:
DRD2
Uniprot ID:
P14416
Molecular Weight:
50618.91 Da
References
  1. Peddi S, Roth BL, Glennon RA, Westkaemper RB: Structural determinants for high 5-HT(2A) receptor affinity of spiro[9,10-dihydroanthracene]-9,3(')-pyrrolidine (SpAMDA). Bioorg Med Chem Lett. 2004 May 3;14(9):2279-83. [PubMed:15081025 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization
Specific Function:
Pore-forming (alpha) subunit of voltage-gated inwardly rectifying potassium channel. Channel properties are modulated by cAMP and subunit assembly. Mediates the rapidly activating component of the delayed rectifying potassium current in heart (IKr). Isoforms USO have no channel activity by themself, but modulates channel characteristics by forming heterotetramers with other isoforms which are r...
Gene Name:
KCNH2
Uniprot ID:
Q12809
Molecular Weight:
126653.52 Da
References
  1. Teschemacher AG, Seward EP, Hancox JC, Witchel HJ: Inhibition of the current of heterologously expressed HERG potassium channels by imipramine and amitriptyline. Br J Pharmacol. 1999 Sep;128(2):479-85. [PubMed:10510461 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Monoamine transmembrane transporter activity
Specific Function:
Amine transporter. Terminates the action of dopamine by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name:
SLC6A3
Uniprot ID:
Q01959
Molecular Weight:
68494.255 Da
References
  1. Melikian HE, Buckley KM: Membrane trafficking regulates the activity of the human dopamine transporter. J Neurosci. 1999 Sep 15;19(18):7699-710. [PubMed:10479674 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
activator
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Beta-arrestin family members inhibit signaling via G pro...
Gene Name:
HTR1A
Uniprot ID:
P08908
Molecular Weight:
46106.335 Da
References
  1. Haddjeri N, Blier P, de Montigny C: Long-term antidepressant treatments result in a tonic activation of forebrain 5-HT1A receptors. J Neurosci. 1998 Dec 1;18(23):10150-6. [PubMed:9822768 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Serotonin receptor activity
Specific Function:
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor is mediated by G proteins that stimulate adenylate cyclase. It has a high affinity for tricyclic psychotropic drugs (By similarity). Controls pyramidal neurons migration during corticogenesis, through...
Gene Name:
HTR6
Uniprot ID:
P50406
Molecular Weight:
46953.625 Da
References
  1. Grimaldi B, Bonnin A, Fillion MP, Ruat M, Traiffort E, Fillion G: Characterization of 5-ht6 receptor and expression of 5-ht6 mRNA in the rat brain during ontogenetic development. Naunyn Schmiedebergs Arch Pharmacol. 1998 Apr;357(4):393-400. [PubMed:9606024 ]
  2. Roth BL: Multiple serotonin receptors: clinical and experimental aspects. Ann Clin Psychiatry. 1994 Jun;6(2):67-78. [PubMed:7804391 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Koyama E, Chiba K, Tani M, Ishizaki T: Reappraisal of human CYP isoforms involved in imipramine N-demethylation and 2-hydroxylation: a study using microsomes obtained from putative extensive and poor metabolizers of S-mephenytoin and eleven recombinant human CYPs. J Pharmacol Exp Ther. 1997 Jun;281(3):1199-210. [PubMed:9190854 ]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Shin JG, Park JY, Kim MJ, Shon JH, Yoon YR, Cha IJ, Lee SS, Oh SW, Kim SW, Flockhart DA: Inhibitory effects of tricyclic antidepressants (TCAs) on human cytochrome P450 enzymes in vitro: mechanism of drug interaction between TCAs and phenytoin. Drug Metab Dispos. 2002 Oct;30(10):1102-7. [PubMed:12228186 ]
  2. Morinobu S, Tanaka T, Kawakatsu S, Totsuka S, Koyama E, Chiba K, Ishizaki T, Kubota T: Effects of genetic defects in the CYP2C19 gene on the N-demethylation of imipramine, and clinical outcome of imipramine therapy. Psychiatry Clin Neurosci. 1997 Aug;51(4):253-7. [PubMed:9316174 ]
  3. Madsen H, Rasmussen BB, Brosen K: Imipramine demethylation in vivo: impact of CYP1A2, CYP2C19, and CYP3A4. Clin Pharmacol Ther. 1997 Mar;61(3):319-24. [PubMed:9084457 ]
  4. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  5. Koyama E, Chiba K, Tani M, Ishizaki T: Reappraisal of human CYP isoforms involved in imipramine N-demethylation and 2-hydroxylation: a study using microsomes obtained from putative extensive and poor metabolizers of S-mephenytoin and eleven recombinant human CYPs. J Pharmacol Exp Ther. 1997 Jun;281(3):1199-210. [PubMed:9190854 ]
  6. Obach RS, Reed-Hagen AE: Measurement of Michaelis constants for cytochrome P450-mediated biotransformation reactions using a substrate depletion approach. Drug Metab Dispos. 2002 Jul;30(7):831-7. [PubMed:12065442 ]
  7. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Brosen K: Drug interactions and the cytochrome P450 system. The role of cytochrome P450 1A2. Clin Pharmacokinet. 1995;29 Suppl 1:20-5. [PubMed:8846619 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  3. Koyama E, Chiba K, Tani M, Ishizaki T: Reappraisal of human CYP isoforms involved in imipramine N-demethylation and 2-hydroxylation: a study using microsomes obtained from putative extensive and poor metabolizers of S-mephenytoin and eleven recombinant human CYPs. J Pharmacol Exp Ther. 1997 Jun;281(3):1199-210. [PubMed:9190854 ]
  4. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Koyama E, Chiba K, Tani M, Ishizaki T: Reappraisal of human CYP isoforms involved in imipramine N-demethylation and 2-hydroxylation: a study using microsomes obtained from putative extensive and poor metabolizers of S-mephenytoin and eleven recombinant human CYPs. J Pharmacol Exp Ther. 1997 Jun;281(3):1199-210. [PubMed:9190854 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Molecular Weight:
56277.81 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP2C18
Uniprot ID:
P33260
Molecular Weight:
55710.075 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic or carcinogenic forms.
Gene Name:
CYP2E1
Uniprot ID:
P05181
Molecular Weight:
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
no
General Function:
Not Available
Specific Function:
Functions as transport protein in the blood stream. Binds various ligands in the interior of its beta-barrel domain. Also binds synthetic drugs and influences their distribution and availability in the body. Appears to function in modulating the activity of the immune system during the acute-phase reaction.
Gene Name:
ORM1
Uniprot ID:
P02763
Molecular Weight:
23511.38 Da
References
  1. Ferry DG, Caplan NB, Cubeddu LX: Interaction between antidepressants and alpha 1-adrenergic receptor antagonists on the binding to alpha 1-acid glycoprotein. J Pharm Sci. 1986 Feb;75(2):146-9. [PubMed:2870173 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Secondary active organic cation transmembrane transporter activity
Specific Function:
Translocates a broad array of organic cations with various structures and molecular weights including the model compounds 1-methyl-4-phenylpyridinium (MPP), tetraethylammonium (TEA), N-1-methylnicotinamide (NMN), 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP), the endogenous compounds choline, guanidine, histamine, epinephrine, adrenaline, noradrenaline and dopamine, and the drugs quinine...
Gene Name:
SLC22A1
Uniprot ID:
O15245
Molecular Weight:
61153.345 Da
References
  1. Urakami Y, Okuda M, Masuda S, Akazawa M, Saito H, Inui K: Distinct characteristics of organic cation transporters, OCT1 and OCT2, in the basolateral membrane of renal tubules. Pharm Res. 2001 Nov;18(11):1528-34. [PubMed:11758759 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, Adkison KK, Polli JW: Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther. 2002 Dec;303(3):1029-37. [PubMed:12438524 ]
  2. Nagy H, Goda K, Fenyvesi F, Bacso Z, Szilasi M, Kappelmayer J, Lustyik G, Cianfriglia M, Szabo G Jr: Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies. Biochem Biophys Res Commun. 2004 Mar 19;315(4):942-9. [PubMed:14985103 ]
  3. Faassen F, Vogel G, Spanings H, Vromans H: Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs. Int J Pharm. 2003 Sep 16;263(1-2):113-22. [PubMed:12954186 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Quaternary ammonium group transmembrane transporter activity
Specific Function:
Mediates tubular uptake of organic compounds from circulation. Mediates the influx of agmatine, dopamine, noradrenaline (norepinephrine), serotonin, choline, famotidine, ranitidine, histamin, creatinine, amantadine, memantine, acriflavine, 4-[4-(dimethylamino)-styryl]-N-methylpyridinium ASP, amiloride, metformin, N-1-methylnicotinamide (NMN), tetraethylammonium (TEA), 1-methyl-4-phenylpyridiniu...
Gene Name:
SLC22A2
Uniprot ID:
O15244
Molecular Weight:
62579.99 Da
References
  1. Urakami Y, Akazawa M, Saito H, Okuda M, Inui K: cDNA cloning, functional characterization, and tissue distribution of an alternatively spliced variant of organic cation transporter hOCT2 predominantly expressed in the human kidney. J Am Soc Nephrol. 2002 Jul;13(7):1703-10. [PubMed:12089365 ]
  2. Urakami Y, Okuda M, Masuda S, Akazawa M, Saito H, Inui K: Distinct characteristics of organic cation transporters, OCT1 and OCT2, in the basolateral membrane of renal tubules. Pharm Res. 2001 Nov;18(11):1528-34. [PubMed:11758759 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Toxin transporter activity
Specific Function:
Mediates potential-dependent transport of a variety of organic cations. May play a significant role in the disposition of cationic neurotoxins and neurotransmitters in the brain.
Gene Name:
SLC22A3
Uniprot ID:
O75751
Molecular Weight:
61279.485 Da
References
  1. Wu X, Huang W, Ganapathy ME, Wang H, Kekuda R, Conway SJ, Leibach FH, Ganapathy V: Structure, function, and regional distribution of the organic cation transporter OCT3 in the kidney. Am J Physiol Renal Physiol. 2000 Sep;279(3):F449-58. [PubMed:10966924 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Symporter activity
Specific Function:
Sodium-ion dependent, low affinity carnitine transporter. Probably transports one sodium ion with one molecule of carnitine. Also transports organic cations such as tetraethylammonium (TEA) without the involvement of sodium. Relative uptake activity ratio of carnitine to TEA is 1.78. A key substrate of this transporter seems to be ergothioneine (ET).
Gene Name:
SLC22A4
Uniprot ID:
Q9H015
Molecular Weight:
62154.48 Da
References
  1. Wu X, George RL, Huang W, Wang H, Conway SJ, Leibach FH, Ganapathy V: Structural and functional characteristics and tissue distribution pattern of rat OCTN1, an organic cation transporter, cloned from placenta. Biochim Biophys Acta. 2000 Jun 1;1466(1-2):315-27. [PubMed:10825452 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23